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The most exciting phrase to hear in science, the one that heralds 
new discoveries, is not ‘Eureka!’ (I found it!) but ‘That’s funny ...’. 
Isaac Asimov
Aan Yvonne, Lisette, Céline en Florence
Aan mijn moeder
In liefdevolle herinnering aan mijn vader
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Monoclonal proteinaemia (M-proteinaemia) is a common finding in the blood of peo-
ple aged 50 years and above. It is usually associated with multiple myeloma, non-
Hodgkin’s lymphoma, or other haematological diseases, respectively. However, in the
majority of cases no related disease is present. The unravelling of a connection between
the clinical finding of M-proteinaemia and the underlying disorder has started more
than 150 years ago and albeit huge advances since, some features are still ill-defined.
History of monoclonal proteinaemia
First description of a monoclonal protein
In September 1844 a wealthy London grocer developed chest pains for which he vis-
ited Dr Thomas Watson, a leading general practitioner of London. Initially, a plas-
ter cast and steel and quinine helped but after several months he developed severe
pains in the chest and back with oedema. Dr William Macintyre, physician to the
8
Figure 1. Detail of the first page of the paper by Dr William Macintyre.
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Metropolitan Convalescent Institution and the Western General Dispensary in St.
Marylebone was called in1.
Because of the oedema Dr Macintyre examined the patient’s urine and noted the
peculiar reaction of the urine when it was heated, cooled and reheated1. Both physi-
cians independently sent a urine sample for analysis to Dr Henry Bence Jones, a 31-
year old chemical pathologist at St George’s hospital. The specimen sent by Dr
Watson was accompanied with the following note:
Figure 2. Detail of the first page of the paper by Henry Bence Jones.
Bence Jones carried out extensive chemical analyses on this unusual heat-precipitable
substance and concluded that it was the ‘the hydrated deutoxide of albumen’2.
According to his estimate, the enormous quantities of this particular albuminous sub-
stance voided in the urine were in the same concentration as albumen in the serum.
No amount of food could compensate for such a loss.
The patient died on January 2, 1846*. At autopsy the sternum, cervical, thoracic and
lumbar vertebrae were soft, fragile and easily breakable and could be cut with a knife.
This abnormal softness of the bones was named ‘mollities ossium’. Histological exam-
ination of the affected bones was made by John Dalrymple, surgeon to the Royal
Ophthalmic Hospital and a member of the Microscopical Society. He described great
numbers of nucleated cells, of variable size and shape, and often larger than an ery-
throcyte. They contained frequently two or three nuclei. These descriptions, though
9
*) The identity of the patient in this first recorded case of multiple myeloma remained unknown for more
than a century. Macintyre referred to him only as Mr M., and Bence Jones never identified him by name.
In 1967 by careful and meticulous research of the Register of Deaths for the London area for the first
quarter of 1846, and by process of elimination based on the known information of age, date of death,
occupation and cause of death the correct death certificate was found3. The patient was identified as
Thomas Alexander McBean and the cause of death was given as atrophy from albuminuria. At that
time the term ‘albuminuria’ was equivocal to proteinuria.
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incomplete, are not inconsistent with malignant plasma cells4. He also noticed the high
degree of vascularity in the diseased bone:
Figure 3. First description of bone marrow hypervascularity by Dr John Dalrymple.
All three physicians Dalrymple, Bence Jones and Macintyre believed this disorder to
be a malignant bone disease.
With the following statement Dr Bence Jones emphasized the role of ‘albumeno-
suria’ in the diagnosis of multiple myeloma: ‘This substance must again be looked
for in acute cases of mollities ossium’. Hereby the first monoclonal protein, and the
first tumour marker, the ‘Bence Jones protein’ had been described2.
From ‘mollities ossium’ to multiple myeloma
Two years before the death of Mr M., another and probably the first description of
possible multiple myeloma was given in 1884 by Solly as ‘mollities ossium’5. The
patient he described was a 39-year-old woman who died four years after an illness that
caused progressive bone pains, kyphoscoliosis and eventually spontaneous fractures
of both clavicles, the right arm and both thighs. Her appetite was failing despite an
allowance of wine, arrow-root, a mutton chop, a pint of porter and an infusion of
orange peel, a rhubarb pill and (luckily) an opiate at night. On autopsy multiple frac-
tures were present with fragile bones with ‘an unnatural degree of vascularity’.
Microscopic examination revealed numerous oval cells with one, rarely two, bright
central nuclei5. In 1873 von Rustizky described the particular pathology of this con-
dition with multiple tumours of the bone marrow and named it ‘multiple myeloma’6.
Introduction
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Another famous case of multiple myeloma (MM) was described in 1889 by Dr Otto
Kahler. A 46-year-old physician named Dr Loos suffered from severe pains in the
ribs, spine, left shoulder and right clavicle. Albuminuria was first noted after two
years, after which anaemia, severe kyphosis, recurrent bronchial infections and loss
of height occurred. On autopsy masses containing large round cells in ribs and tho-
racic vertebrae were seen. Kahler recognized that the urinary protein had the same
characteristics as those described by Bence Jones7 and the urine was described in
detail by Huppert8. In 1900 Wright was the first to identify the plasma cells as tumour
cells MM9.
The name multiple myeloma stuck until today, though this disease is still often
referred to as ‘Kahler’s disease’ in The Netherlands and ‘Rustizky’s disease’ in Russia.
11
Figure 4. Chemical analysis and description of the urinary light chain protein by
Henry Bence Jones.
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Aside from diagnostic advances in serum protein examinations ante mortem recog-
nition of MM was greatly enhanced by utilizing X-rays10 and bone marrow exami-
nation11. No effective treatment was found until 1947 when urethane was discovered
and followed 15 years later by melphalan (L-phenylalanine mustard)12, which
remained the cornerstone of MM-therapy up till the last decade of the last century.
As the main scope of this historic introduction is on monoclonal proteinaemia I will
not further elaborate on the history of the diagnostic and therapeutic advances in
MM.
Bence Jones protein: source and kinetics
In 1846, J.F. Heller described a protein in the urine that precipitated when warmed
a little above 50 °C (122 °F) and disappeared on further heating. Although Heller
did not recognize the precipitation of the protein when the urine was cooled, it is
almost certain that this was Bence Jones protein. He distinguished this new protein
from albumin and casein13. Dr R. Fleisher, a clinical physicist who investigated nor-
mal and pathological bone marrow (knochenmark) was the first to use the term ‘Bence
Jones protein’14.
Bradshaw found that meals had little or no influence on the amount of Bence Jones
proteinuria. There was no nocturnal variation and the excretion rate was believed to
be fairly constant during the day15. Walters made a study of three patients and con-
firmed that the quantity of Bence Jones proteinuria was independent of the protein
intake. Furthermore, no diurnal variation was found. Bence Jones protein was demon-
strated in the blood of one patient and in the bronchial secretions of another. Walters
concluded that Bence Jones protein was of endogenous origin and was probably
derived from blood proteins through the action of abnormal cells in the bone mar-
row16. In this era before the rise of medical ethical committees one patient was even
given an intravenous injection of Bence Jones protein which appeared to increase the
amount of Bence Jones proteinuria. This first intra-venous injection of a MOAB
(MOnoclonal AntiBody) ever reported was not surprisingly, however, accompanied
by cold chills and shivering for up to two hours16!
Two distinct groups of Bence Jones proteins were recognized by Bayne-Jones and
Wilson in 1922. They demonstrated that Bence Jones proteins consisted of a group
of similar, but not identical, proteins. They made 12 preparations of Bence Jones
proteins from five patients and immunized rabbits by intravenous injection of the
Bence Jones protein and next precipitin tests were performed with the Bence Jones
preparations. Two distinct groups were found and designated group I and group II17.
In 1956 Korngold and Lippari identified three different Bence Jones proteins using
the Ouchterlony test, but two were always found together in the urine of the same
patient. They showed that anti-sera to Bence Jones protein also reacted with myeloma
proteins18. Later, as a tribute to Korngold and Lippari, the two classes of Bence Jones
proteins have been designated kappa and lambda (κ and λ)18.
Introduction
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Using 13C-labelled glycine, Putnam and Hardy demonstrated in 1955 that synthesis
of the abnormal serum globulin and that of Bence Jones protein were independent
processes. Bence Jones protein was found to be rapidly excreted and was thought to
be derived from the nitrogen pool rather than from the plasma or a tissue protein
precursor19.
In 1962, more than a century after the description of the unique heat properties,
Edelman and Gally showed that the light chains prepared from an IgG monoclonal
protein and the Bence Jones protein from the same patient’s urine had an identical
amino acid composition, similar spectrofluorometric behaviour, identical appearance
on chromatography on carboxymethylcellulose and on starch gel electrophoresis after
reduction and alkylation, the same ultracentrifugal pattern, identical thermal solubility
and the same molecular weight. These chains precipitated when heated to between
40 °C (104 °F) and 60 °C (140 °F), dissolved on boiling and re-precipitated with cool-
ing to between 40 °C and 60 °C, which is identical with the heat properties of the
Bence Jones proteins20.
Serum gammaglobulins and monoclonal proteinaemia
A specific substance with neutralizing activity (antibody) was described in 1890 in the
blood of animals immunized with diphtheria and tetanus toxin21. Tiselius used the
moving boundary method of electrophoresis in his doctoral dissertation in 1930 to
demonstrate the homogeneity of serum globulins. His manuscript describing the
apparatus for electrophoresis was not accepted by the Biochemical Journal, because
it was considered too physical. Next it was published in the Transactions of the
Faraday Society22, eventually this article led to the Nobel Prize and the presidency
of the Nobel foundation. Later that same year, Tiselius described the separation of
serum globulins into three components, which he designated α, β, and γ23. Two years
later, Tiselius located antibody activity in the gammaglobulin fraction of plasma pro-
teins. They noted that antibodies to Pneumococcus type I were found in the area of
γ mobility in rabbit serum and that antibodies to pneumococcal organisms migrated
between β and γ in horse serum24. Hyperproteinaemia as a feature of MM was rec-
ognized by Perlzweig in 1927 before the discovery of protein electrophoresis. He
demonstrated Bence Jones proteins in both urine and blood in the same patient25.
Longsworth et al applied electrophoresis to the study of multiple myeloma and
demonstrated the tall narrow-based church spire peak26. As Tiselius apparatus was
cumbersome to use paper electrophoresis became more popular and in turn was
replaced by cellulose acetate. Currently, high-resolution electrophoresis on agarose
gel is employed in most laboratories.
Grabar and Williams described immunoelectrophoresis, which facilitated the diag-
nosis of multiple myeloma27. Immunofixation or direct immunoelectrophoresis was
described by Wilson when he applied the antisera on the surface of the agar directly
after the completion of electrophoresis28. Immunofixation is useful in the recognition
13
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of small monoclonal light chains when none are found in immunoelectrophoresis29.
When combined with immunofixation, high resolution agarose gel electrophoresis is
more sensitive than immunoelectrophoresis in detecting small monoclonal proteins30.
Kunkel believed that monoclonal proteins were the equivalent of normal antibodies
produced by normal plasma cells. He showed that each heavy chain subclass and light
chain type in monoclonal proteins had its counterpart among normal immunoglob-
ulins and also among antibodies. After the discovery of the two types of light chains,
κ and λ, in the monoclonal proteins of a ratio of approximately 2:1, the same ratio was
detected among normal immunoglobulins. Similarly like IgG, IgA31 and IgD32 iso-
types were discovered among myeloma proteins and were then found as normal serum
components33. It was recognized that some antibodies migrate in the fast γ region
and that some sediment in the ultracentrifuge at 7S and others at 19S. Strangely, the
concept of a family of proteins with antibody activity was not proposed until the late
1950’s by Heremans34. The term gammaglobulin was used for any protein that
migrated in the γ region during electrophoresis, later these were divided as immuno-
globulins IgG, IgA, IgM, IgD and IgE.
The concept of polyclonal versus monoclonal gammopathies was lucidly presented by
Waldenström in the Harvey lectures35. In that same year he already had described a
series of patients with a heavy M-protein; ‘macroglobulin’, and a clinical picture
different from MM often presenting with lymph-node enlargement and hepato-
splenomegaly36. Rather quick this syndrome was referred to as Waldenström’s macro-
globulinaemia. He then clearly described patients with a narrow band of hyper-
gammaglobulinaemia as having a paraprotein (monoclonal protein). Although many
of these patients had multiple myeloma or macroglobulinaemia others had no evidence
of malignancy and were considered as having ‘essential hypergammaglobulinaemia’
or ‘benign monoclonal gammopathy’35. This distinction is very important as a mon-
oclonal gammopathy can indicate a malignant process whereas patients with a poly-
clonal gammopathy usually have a reactive or inflammatory cause35.
Since the 1950’s, with increasing deployment of serum protein-electrophoresis an
increasing number of (case) reports of monoclonal gammopathies in the absence of
MM or macroglobulinaemia were reported. Many names have been given for this
condition (Table 1). The frequency of M-proteinaemia not apparently related to a
malignant disease turned out to be relatively high and increased during advanced age
with a prevalence of 1.5-3% in persons of 70 years and older37-40. The need was felt
for both physicians and their patients for easily obtainable screening clues whether the
M-protein would remain stable or whether it would progress to MM, macroglobuli-
naemia or another haematological malignancy. That this was a real risk was demon-
strated by Kyle by close monitoring of 241 persons with ‘benign’ M-proteinaemia. In
a relatively short five year follow-up 11% developed an M-proteinaemia related malig-
nancy41. Hence this condition could not be termed ‘benign’ and thus the term
Monoclonal Gammopathy of Unknown Significance ‘MGUS’ was coined. During
Introduction
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longer follow-up of median 22 (20-35) years of the same group of persons with MGUS
24% ultimately developed a related haematological malignancy42. In the largest ret-
rospective follow-up study on MGUS thus far (1384 patients) the yearly risk of pro-
gression to MM or a related disorder was demonstrated to be 1%43.
Monoclonal protein detection in 2005
There are several methodologies available for the detection of an M-protein in serum
or urine. The tests are described in logical order (e.g. screening and then elaborate
determination of the heavy class and light chain type) and divided in serum and urine
tests.
Serum analysis
Analysis of serum for the presence of M-proteins is usually performed after clinical
suspicion on the presence of an M-protein related disorder has risen (e.g. elevation
of the erythrocyte sedimentation rate or serum viscosity, anaemia, back pain, weak-
ness or fatigue, osteopenia, osteolytic lesions, or spontaneous fractures, renal insuf-
ficiency with a bland urine sediment, heavy proteinuria in a patient over age 50, hyper-
calcaemia, hypergammaglobulinaemia, immunoglobulin deficiency, Bence Jones
proteinuria, or recurrent infections). Initially electrophoretic techniques are used,
supplemented with additional tests for protein quantification and methodologies to
determine whether the protein is indeed monoclonal (arises from a single clone of
plasma cells).
Serum protein electrophoresis: Serum protein electrophoresis (SPE) is an inexpensive and
easy to perform screening procedure. Agarose gel electrophoresis is the recommended
method for the detection of an M-protein. In the electrophoretic methodologies,
proteins are classified by their final position after electrophoresis is complete into
five general regions: albumin, α-1, α-2, β and γ (Figure 5).
These regions, which also use a Greek lettering system, do not refer to the
immunoglobulin class to which an M-protein may belong, and refer only to mobil-
ity through the support medium. The various immunoglobulin classes (IgG, IgA,
IgM, IgD, and IgE) are usually of γ mobility and make up most of the γ region, but
they may also be found in the β-γ and β regions, and may occasionally extend into the
α-2 globulin area. SPE should always be performed in combination with immunofix-
ation in order to determine clonality. An M-protein usually presents as a single nar-
row peak, like a church spire, in the γ, β, or α-2 region of the densitometer tracing
or as a dense, discrete band on the agarose gel. This is in contrast to polyclonal
immunoglobulins which present as a diffuse broad band on the SPE in the γ region.
15
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Figure 5a. Normal serum protein electrophoresis and densitometry.
Introduction
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Figure 5b. Serum protein electrophoresis with subsequent densitometry and
immunofixation revealing the presence of an IgG-κ M-protein of 21.7 g/l.
17
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Immunofixation
Immunofixation is performed in order to confirm the presence of an M-protein and
to determine its type. In immunofixation, the patient’s serum is electrophoresed into
at least five separate lanes. Following electrophoretic separation of the serum proteins,
each sample is overlaid with a different monospecific antibody, usually three for the
heavy chain component and two for the light chain component (e.g., anti-γ, anti-µ,
anti-α, anti-κ, and anti-λ, respectively). Precipitation of proteins (i.e., the antigen-anti-
body complex) is allowed to occur, followed by washing (nonprecipitated proteins
wash out) and staining of the remaining immunoprecipitates. An M-protein is char-
acterized on immunofixation by the combined presence of a sharp, well-defined band
associated with a single heavy-chain class and a sharp and well-defined band with
similar mobility characteristics which reacts with either κ or λ light chain antisera, but
not both (Figure 6).
Other reasons for immunofixation can be: detection of a small amount of M-protein
in the presence of normal or increased background immunoglobulins, recognition
and distinction of biclonal or triclonal gammopathies. Furthermore, the possibility of
IgD and IgE monoclonal proteins must be excluded by immunofixation using IgD and
IgE antisera in all patients with a monoclonal light chain in the serum or urine but
no reactivity to anti-G, anti-M, or anti-A.





ELP G A M K L
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Immunoelectrophoresis: Immunoelectrophoresis differs from immunofixation in that
the end-point is a precipitin arc rather than a distinct band; most laboratories rely on
immunofixation techniques.
Quantization of immunoglobulins: Quantization of immunoglobulins is the most use-
ful technique for the detection of hypogammaglobulinaemia. The use of a rate neph-
elometer is a good method for this purpose. The degree of turbidity produced by
antigen-antibody interaction is measured by nephelometry in the near ultraviolet
regions. Because the method is not affected by the molecular size of the antigen, the
nephelometric technique accurately measures IgM, polymers of IgA, or aggregates of
IgG.
Capillary zone electrophoresis: Capillary zone electrophoresis measures protein on-line
via light absorbance techniques; protein stains are not necessary and no point of appli-
cation is seen. The electrophoretograms are similar to those seen with high resolu-
tion agarose gel serum protein electrophoresis. Following capillary electrophoresis,
immunotyping can be performed by an immunosubtraction procedure in which the
serum sample is incubated with sepharose beads coupled with anti-γ, -α, -µ, -κ, and
-λ antisera. After incubation with each of the heavy and light chain antisera, the super-
natants are reanalyzed to determine which reagent(s) removed the electrophoretic
abnormality. Capillary electrophoresis appears to be slightly more sensitive than
agarose gel electrophoresis. The immunosubtraction procedure is technically less
demanding, is automated, and is therefore a useful procedure for immunotyping M-
proteins.
Free light chains in serum: Immunoassays are now available for detection of low con-
centrations of monoclonal free light chains in serum44. Using this assay Drayson et
al reported that 68% of patients previously diagnosed as having nonsecretory myeloma
were reclassified as light chain myeloma45. Measurement of free light chains may be
useful in diagnosis and monitoring progress of patients with light chain myeloma,
primary systemic amyloidosis, and in patients after high dose chemotherapy for MM44.
Analysis of urine
Dipstick testing: Dipsticks are used in many laboratories to screen for the presence of
protein in the urine. The dipstick is impregnated with a buffered indicator dye that
binds to protein and produces a colour change proportional to the amount of protein
bound to it. However, dipsticks are insensitive to the presence of Bence Jones pro-
tein (free κ or λ light chains) and should not be used for this purpose.
Sulfosalicylic acid test: The SSA test is performed by mixing one part urine supernatant
(e.g., 2.5 ml) with three parts 3 percent sulfosalicylic acid, and semiquantative grad-
ing of the resultant turbidity. When proteinuria is present but the dipstick test is neg-
ative this should heighten the suspicion of Bence Jones proteinuria. Immunofixation
of an adequately concentrated urine specimen is the following recommended test.
19
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24-hour urine collection: Patients with a serum M-protein concentration >1.5 g/dl or
those with a diagnosis or clinical suspicion of a plasma cell dyscrasia should have elec-
trophoresis and immunofixation of an aliquot from a 24-hour urine collection. A 24-
hour urine collection is necessary for determination of the total amount of protein
excreted in the urine per day. The quantity of M-protein excreted is determined by
measuring the size (percent) of the M-spike in the densitometer tracing and multi-
plying it by the total 24-hour urinary protein excretion. The amount of protein can
be expressed as mg/dl or mg/l but it is much more useful to report the M-protein in
g/24 hours because of wide variability in the daily urinary volume. The 24-hour urine
specimen requires no preservative and may be kept at room temperature during col-
lection. Generally, the amount of urinary monoclonal protein correlates directly with
the size of the plasma cell burden, as long as renal function is relatively normal.
Consequently, urinary M-protein excretion is useful in determining the response to
chemotherapy or progression of disease.
Immunofixation: Immunofixation is the logical next method for identification of a
monoclonal protein in the urine. Immunofixation can be performed even if the rou-
tine urine analysis is negative for protein, 24-hour urine protein concentration is
within normal limits, and electrophoresis of a concentrated urine specimen shows no
globulin peak. Immunofixation is sufficiently sensitive to detect a urine M-protein of
0.04 g/l.
Current classification system on monoclonal proteinaemia
Recently a new and classification system was developed for the monoclonal gam-
mopathies by The International Myeloma Working Group46. The rationale was to
use simple and easily obtainable criteria based on routinely available laboratory tests
rather than attempting to cover all diagnostic situations46. This will result in defini-
tions that will be easy to accept and to use in everyday practice and will facilitate the
comparison of data of diverse investigations and therapeutic trail data46. These guide-
lines are found in Table 2. For comparison, older classification systems by Durie and
Salmon47, Kyle and Greipp48, and the British Columbia Cancer Agency (BCCA)49 are
shown in Table 3.
The CCCW-paraprotein database
Considering the historic development in the detection of MGUS a ‘Paraprotein Task
Force’ was initiated by the Comprehensive Cancer Centre West in the Western part
of The Netherlands. The final goals were to develop guidelines for physicians on
Introduction
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MGUS and furthermore to develop a population-based M-protein registry in which
patients with MGUS could be followed prospectively.
From 1991 till 1993 a population-based registry on M-proteinaemia was carried out
in the region of the Comprehensive Cancer Centre West (CCCW), a geographical
area with 1.6 million inhabitants. Clinical chemists, internists, haematologists, pathol-
ogists and other physicians reported all patients with newly diagnosed M-proteinaemia
or multiple myeloma in the CCCW-area. Information on patient characteristics, lab-
oratory test results, and results of bone marrow examination and skeletal x-rays were
documented. The M-protein-related diagnosis, comorbidity and therapy were
recorded and a serum sample was frozen at -80 °C. Follow-up was done annually. At
follow-up, clinical data, any evolution into MM or other haematological malignancy,
as well as comorbidity were recorded. In total, 1464 patients have been registered. This
registry has already resulted in one thesis50 and has been described in detail before50.
Aims of this thesis
In the present thesis we first examine in Chapters Two and Three the discrimina-
tory value of serum interleukin-6 and serum syndecan-1 in patients with newly diag-
nosed MGUS as both are important in MM-bone marrow interactions and have been
reported to be of prognostic value in MM. We focus in Chapter Four on the prob-
able association between M-proteinaemia and non-haematological malignancies (‘solid
tumours’) as a relation is suggested in the older literature. Long term prognosis in
MGUS is discussed in Chapter Five with a prospective follow-up of the whole
CCCW-cohort. Finally, in Chapters Six and Seven the focus is more on MM ther-
apy. In Chapter Six we examine the relationship between response to treatment as
determined by the M-protein decrement found during melphalan-prednisone (MP)
therapy during the HOVON-16 trial. In Chapter Seven the role of interferon-α as
maintenance therapy after MP-induction therapy is discussed with an emphasis on
quality of life.
21
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Table 1. Synonyms for MGUS.
Synonym Year Author
Essential hyperglobulinaemia 1952 Waldenström51
Benign proteinaemia 1955 Olhagen-Liljestrand52
Nonmyelomatous paraproteinaemia 1957 Smith53
Dysgammaglobulinemic syndrome 1959 Hammack et al54
Atypical dysproteinaemia 1959 Creyssel et al55
Symptomless myelomatosis 1959 Baker-Martin56
γ1-syndrome 1960 Schettler
57
Essential, monoclonal benign hypergamma-
globulinaemia 1961 Waldenström35
Cryptogenic transitory paraproteinaemia 1961 Schobel58
Essential hyperdysglobulinaemia 1961 Olmer et al59
Facultative paraproteinaemia 1961 Spengler60
Monoclonal gammopathy of unknown etiology 1963 Osserman61
Rudimentary paraproteinaemia 1963 Märki62
Benign, essential monoclonal non-macro-
molecular hypergammaglobulinaemia 1964 Waldenström63
Begleitparaproteinämie 1964 Riva64
Secondary paraproteinaemia 1964 Videbaek65
Idiopathic paraproteinaemia 1964 Rádl66
Lanthanic proteinaemia 1967 Zawadski67
Asymptomatic paraimmunoglobulinaemia 1969 Engle68
Asymptomatic paraproteinaemia 1972 Meijers69
Nonmyelomatous monoclonal immuno-
globulinaemia 1972 Zawadski70
Accompanying paraproteinaemia 1972 Siebner71
Asymptomatic or occult plasma cell dyscrasias 1972 Isobe72
MGUS (Monoclonal Gammopathy of -
Undetermined Significance) 1978 Kyle73
Introduction
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Table 2. Diagnostic criteria in monoclonal proteinaemia according to 
The International Myeloma Working Group.
Monoclonal gammopathy of unknown significance
M-protein in serum <30 g/l
Bone marrow plasma cells <10% and low level of plasma cell infiltration in a trephine
biopsy (if done)
No evidence of B-cell proliferative disorders
No related organ or tissue impairment (no end organ damage, including bone lesions)
Asymptomatic myeloma (smouldering myeloma)
M-protein in serum ≥30 g/l
and/or
Bone marrow plasma cells ≥10%
No related organ or tissue impairment (no end organ damage, including bone lesions) or
symptoms
Symptomatic multiple myeloma
M-protein in serum and/or urine
Bone marrow (clonal) plasma cellsa or plasmocytoma
Related organ or tissue impairment (no end organ damage, including bone lesions) or
symptoms
a) If flowcytometry is performed most plasma cells (>90%) will show a ‘neoplastic’ phenotype.
Some patients may have no symptoms but have related organ or tissue impairment.
Non-secretory myeloma
No M-protein in serum and/or urine with immunofixation
Bone marrow clonal plasmacytosis ≥10% or plasmocytoma
Related organ or tissue impairment (no end organ damage, including bone lesions)
Solitary plasmacytoma of bone
No M-protein in serum and/or urine with immunofixationc
Single area of bone destruction due to clonal plasma cells
Bone marrow not consistent with multiple myeloma
Normal skeletal survey (and MRI of spine and pelvis if done)
No related organ or tissue impairment (no end organ damage other than solitary bone
lesion) or symptoms
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Extramedullary plasmacytoma
No M-protein in serum and/or urine with immunofixationb
Extramedullary tumour of plasma cells
Normal bone marrow
Normal skeletal survey
No related organ or tissue impairment (no end organ damage, including bone lesions) or
symptoms
Multiple solitary plasmacytomas (± recurrent)
No M-protein in serum and/or urine with immunofixationb
More than one localized area of bone destruction or extramedullary tumour of clonal
plasma cells which may be recurrent
Normal bone marrow
Normal skeletal survey (and MRI of spine and pelvis if done)
No related organ or tissue impairment (no end organ damage the localized bone lesions)
b) A small M-component may sometimes be present
Myeloma-related organ or tissue impairment (end organ damage) (ROTI) due to
the plasma cell proliferative process
Calcium levels increased: serum calcium >0.25 mmol/l above the upper limit of normal
or >2.75 mmol/l
Renal insufficiency: creatinine >173 mmol/l
Anaemia: Haemoglobin 2 g/dl below the lower limit of normal or haemoglobin <10 g/dl
Bone lesions: lytic lesions or osteoporosis with compression fractures (MRI or CT may
clarify)
Other: symptomatic hyperviscosity, amyloidosis, recurrent bacterial infections (>2 episodes
in 12 months)
CRAB (calcium, renal insufficiency, and anaemia or bone lesions)
Introduction
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Table 3. Additional monoclonal protein classification systems.
A. Diagnostic criteria according to Durie and Salmon
Multiple myeloma (MM)
Major criteria:
1. Plasmocytoma on tissue biopsy
2. Bone marrow plasmacytosis with ≥30% plasma cells
3. Monoclonal protein serum electrophoresis and immunofixation: IgG >35 g/l, 
IgA >20 g/l, light chain excretion on urine electrophoresis ≥1 g/24 hours in the
absence of amyloidosis
Minor criteria:
a. Bone marrow plasmacytosis with 10 to 30% plasma cells
b. Monoclonal protein serum present, but less than levels defined above
c. Lytic bone lesions
d. Normal IgM < 500 mg/l, IgA < 1 g/l or IgG < 6 g/l
The diagnosis of multiple myeloma requires a minimum of one major and one minor
criterion (1 + a not sufficient) or 3 minor criteria that must include a + b.
Indolent myeloma (IMM)
Criteria as for myeloma with the following limitations:
a. Absent or only limited bone lesions (≤3 lytic lesions), no compression fractures
b. Monoclonal protein serum levels IgG <70 g/l, IgA < 50 g/l
c. No symptoms or associated disease features: Karnofsky performance status >70%,
haemoglobin >6.8 mmol/l, serum calcium normal, serum creatinin <177 µmol/l 
(3.0 mg/dl), no infections
Smouldering multiple myeloma (SMM)
Criteria as for indolent myeloma with additional constraints:
a. There must be no demonstrable bone lesions
b. Bone marrow plasma cells 10-30%
Monoclonal gammopathy of undetermined significance (MGUS)
1. Monoclonal protein levels IgG ≤35 g/l, IgA ≤20 g/l, Bence Jones protein ≤1.0 g/24 hours
2. Bone marrow plasma cells <10%
3. No bone lesions
4. No symptoms
25
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B. Diagnostic criteria according to Kyle and Greipp
Multiple myeloma (MM)
1. M-protein present in serum or urine
2. ≥ 10% bone marrow plasma cells, or aggregates on biopsy
3. One or more ancillary findings, must not be attributable to another cause: 
a. anaemia
b. lytic bone lesions, or osteoporosis and ≥30% plasma cells in bone marrow
c. bone marrow plasma cell labelling index >1%
d. renal insufficiency (adult Fanconi syndrome or light chain deposition disease not
sufficient)
e. hypercalcaemia
Smouldering multiple myeloma (SMM)
1. Serum monoclonal protein (usually >30 g/l) and 10% or more bone marrow plasma
cells or aggregates on biopsy
2. No anaemia, renal failure or hypercalcaemia attributable to myeloma
3. Other ancillary tests negative: 
a. bone lesions absent on radiographic bone survey
b. bone marrow plasma cell labelling index <1%
c. plasmablasts absent
d. normal β-2 microglobulin level in the absence of renal insufficiency, absence 
of circulating isotype specific plasma cells, peripheral blood B-cell labelling index
<0.5%, absence of light chain isotype suppression, urinary light chain 
<0.5 g/24 hours, stable monoclonal protein in serum or urine during follow-up.
Monoclonal gammopathy of undetermined significance (MGUS)
1. Serum monoclonal protein (usually l<30 g/l)
2. No anaemia, renal failure or hypercalcaemia
3. <10% bone marrow plasma cells without aggregates on biopsy
4. Ancillary tests negative (as above)
Solitary plasmacytoma
1. Single plasma cell tumour
2. No diagnostic criteria for systemic multiple myeloma
3. Little or no monoclonal protein after radiotherapy
4. <10% bone marrow plasma cells
Introduction
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C. Diagnostic criteria according to the British Columbia Cancer Agency (BCCA)
Multiple myeloma (MM)
At least two of the following:
1. Monoclonal protein present in serum or urine
2. Lytic bone lesions
3. ≥10% bone marrow plasma cells
Indolent multiple myeloma (IMM)
Criteria as for multiple myeloma with the following additional criteria:
1. No symptoms
2. Satisfactory peripheral blood counts
3. No monoclonal protein in the urine
4. Normal serum calcium
5. Stable monoclonal protein level
6. No lytic bone lesions
7. No renal or neurological disease due to myeloma
Monoclonal gammopathy of undetermined significance (MGUS)
All of these must be present:
1. Serum monoclonal protein
2. No lytic bone lesions
3. Bone marrow plasmacytosis <10%
Solitary plasmacytoma
All these criteria must be present:
1. Biopsy proof of a plasma cell tumour
2. No lytic bone lesions except the tumour itself
3. Bone marrow plasmacytosis <10%
(A serum and/or urine monoclonal protein may be present)
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2 Serum interleukin-6 has no discriminatory role
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Abstract
We determined interleukin-6 (IL-6) in serum of 212 well-defined patients with newly
diagnosed paraproteinaemia and evaluated its discriminatory value and its prognostic
role in multiple myeloma (MM). Results were compared with serum neural cell adhae-
sion molecule and β-2-microglobulin, both established prognostic MM markers.
Paraproteinaemia related diagnoses were: MM (60), other haematological diseases (46),
solid tumours (35), auto-immune diseases (17) and monoclonal gammopathy of
unknown significance (MGUS) (54). IL-6 ranges in all diagnostic groups overlapped
widely and did not serve as a discriminatory marker in newly diagnosed parapro-
teinaemia even when patients with infection or fever (42) were excluded. In MM high
IL-6 levels (≥50 pg/ml) were not associated with a shorter survival (p=0.24). We com-
pared our results with 20 published studies on serum IL-6 in paraproteinaemia and/or
MM. IL-6 data have to be related to the assay used (bio- or immunoassay) and to the
status of MM (newly diagnosed, during therapy, progressive disease). We conclude
that serum IL-6 is not specific for paraproteinaemia-related diseases and will not serve
as a reliable discriminatory or prognostic marker in paraproteinaemia and MM.
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Introduction
Monoclonal gammopathy or paraproteinaemia is not synonymous with multiple
myeloma (MM). At first presentation a diagnosis of MM, plasmacytoma, amyloido-
sis or other haematological malignancy is made in only 37% of these patients1. The
majority of patients with a newly diagnosed paraprotein, does not fulfil the diagnos-
tic criteria for MM and hence are classified as having monoclonal gammopathy of
undetermined significance (MGUS). Follow-up of MGUS patients for more then
twenty years has shown that MM, amyloidosis or other haematological malignancies
arise in 24%, demonstrating that lifelong follow-up is mandatory1.
For newly diagnosed patients with paraproteinaemia the need is felt for an easy (serum)
parameter to distinguish MM from other causes of paraproteinaemia. Interleukin-6
(IL-6) is a potent in vitro and in vivo growth factor for human myeloma cells and has
therefore received much attention as a possible tumour-, disease activity-, and prog-
nostic marker in MM and other causes of paraproteinaemia2. Recently, the diagnos-
tic value of serum neural cell adhesion molecule (NCAM) in newly diagnosed patients
with MM and other well-defined monoclonal gammopathies of different causes was
demonstrated. The specificity was excellent (97%) but the sensitivity was low (52%)3.
We decided to test the diagnostic value of serum IL-6 in paraproteinaemia and its
prognostic value in MM in the same group of patients. Moreover we included the
results with NCAM, C-reactive protein (CRP) and β-2-microglobulin (β2M) in the
analysis of these patients. In addition, we compared our IL-6 data with all published
series available.
Patients and methods
Patients: From 1991 till 1993 a population-based registry on paraproteinaemia was car-
ried out in the region of the Comprehensive Cancer Center West (CCCW). All
patients with newly diagnosed paraproteinaemia and/or multiple myeloma in the
Midwestern part of The Netherlands (1,6 million inhabitants and 15 hospitals in
1992) were reported by clinical chemists, internists, haematologists, pathologists and
other physicians. Information on patient characteristics (age, sex, performance status),
laboratory tests results (haemoglobin, leukocyte- and thrombocyte counts, creatinin,
calcium, albumen, total protein, paraprotein type and concentration in serum and
urine), and results of bone marrow and skeletal x-rays were obtained. The parapro-
tein-related diagnosis, comorbidity and therapy were recorded. A serum sample
obtained at registration was centrally stored at -80 ºC. Follow-up was done at least
once yearly. In total, 1464 patients have been registered. The setup and contents of
this registry have been described4. Paraproteins were either detected by agarose or cel-
lulose-acetate electrophoresis depending on the method used in each hospital where
serum interleukin-6 in paraproteinaemia and multiple myeloma
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the patient was first seen. For inclusion in the registry each paraprotein had to be
confirmed by immunotyping (immunofixation). Serum was available from 867
patients. Out of this series, 212 sera were selected in whom all diagnostic tests had
been performed and a paraprotein-related diagnosis was available3.
Multiple myeloma was diagnosed in 60 patients, other haematological diseases in 46
patients, solid tumour in 35, auto-immune disease in 17 and MGUS in 54 patients.
Different stages among the MM patients were: indolent myeloma 9 cases, stage I 13
cases, stage II 4 cases and stage III 34 cases. Other haematological malignancies con-
sisted of lymphoproliferative diseases: 39 (15 immunocytoma, 18 other B-cell non-
Hodgkin’s lymphoma, 4 B-cell chronic lymphocytic leukaemia, 2 Hodgkin’s disease)
and myeloproliferative diseases: 7 (6 myelodysplastic syndrome, 1 promyelocytic
leukaemia). According to the criteria of the British Columbia Cancer Agency (BCCA)
the diagnosis of MM was made when at least two of the following criteria were pres-
ent: paraprotein in serum and/or urine, lytic bone lesion(s), or more than 10% plasma
cells in bone marrow cytology5;6. A paraprotein in serum (but not in urine), with
more than 10% plasma cells in cytology, in the absence of symptoms, anaemia, leu-
cocytopenia, thrombocytopenia, hypercalciaemia, renal failure due to myeloma or
lytic bone lesions was diagnosed as indolent MM3;5. Any paraprotein without indi-
cation of MM or other (haematological) malignancies, or auto-immune disease with
less than 10% plasma cells in bone marrow cytology was termed MGUS3.
Laboratory Methods: Serum samples stored at -80 ºC were thawed and shipped on ice
to the Marburg University (Germany) where NCAM and IL-6 determinations were
done. For IL-6 determinations an enzyme linked immunoabsorbent assay (LD Zytokit
IL-6 ELISA, LD Labor Diagnostika Heiden, Germany) was used with a sensitivity
of 1 pg/ml. The analyses of β2M, CRP and NCAM have been described before3.
Interassay coefficients of variation for IL-6 were less than 8%, for NCAM 2-8%, for
β2M 7-10% and for CRP less than 8%. Upper normal serum values were 20 U/ml
for NCAM, 3 mg/l for β2M and less than 10 mg/l for CRP. As median values and
ranges for serum IL-6 differ among normal control groups no reference values were
available (see also Table 3). IL-6, NCAM, CRP and β2M were determined in blinded
samples. Other laboratory results were extracted from the registry.
Statistics: The comparison of median values of laboratory parameters for different
diagnostic categories was done using Mann-Whitney’s test (2 groups) or Kruskall-
Wallis test (more than 2 groups). Survival was calculated from diagnosis to death
(event) or to being alive at last follow-up (censoring). Survival curves were made using
the Kaplan Meier methods and compared with the log-rank test. Analyses were per-
formed using SPSS/PC+; data were entered in a database using SPSS Data Entry II
(both SPSS Inc, Chicago, IL).
Literature search: For the period January 1966 to May 1999 we searched the medical
literature in Medline using the items: ‘paraproteinaemia’, ‘monoclonal gammopa-
thy’, ‘interleukin-6’ and ‘multiple myeloma’. All studies on serum IL-6 in patients
with paraproteinaemia and/or MM were reviewed.
Chapter 2
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Results
Interleukin-6: Serum IL-6 was measurable in all 212 patients studied. The median
values and ranges for IL-6, NCAM, CRP and β2M are shown in Table 1. Figure 1
is a graphic display of the individual IL-6 values grouped by diagnostic category. The
median levels of IL-6 showed significant differences between the diagnostic cate-
gories (Kruskall Wallis test, p<0.001), but overlapped widely and none had a charac-
teristic range. IL-6 values correlated with CRP (r=0.42; p<0.0001), but not with
NCAM, osteolysis and β2M. At presentation 42 patients (lymphoproliferative (9),
solid tumour (6), auto-immune disease (2), MGUS (15), MM I (6), MM III (4)) had
either a documented infection or fever without a known cause. Excluding these from
analysis did not make any difference (Table 1, p=0.005).
Figure 1. Range of serum IL-6 in all diagnostic categories. Median levels of serum
IL-6 are depicted as bars. Outliers are represented by an arrow and accompanied by
the actual value. 
Ly-pro: lymphoproliferative disease; 
My-pro: myeloproliferative disease; 
tumour: solid tumour; 
auto-imm: auto-immune disease; 
IMM: indolent MM.
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For practical clinical purposes all diagnostic categories were combined to three major
groups; non-MM (lymphoproliferative, myeloproliferative, solid tumour, and auto-
immune disease), MGUS and MM (IMM, MM I, MM II, MM III). Median serum
IL-6 values in non-MM and MGUS were significantly higher than in patients with
MM (Table 2). IL-6 values in MGUS were higher than in MM though this differ-
ence disappeared after excluding all patients with a documented infection or fever at
diagnosis. β2M and NCAM levels were significantly higher in MM compared to non-
MM and MGUS whereas CRP was higher in the latter two (Table 2).
Serum IL-6 and survival in patients with MM: We investigated whether high IL-6
serum levels at diagnosis were of prognostic significance for survival in patients with
MM. Median time of follow-up was 44 months (range 0-74 months). Patients with
MM and initial high values of IL-6 (≥50 pg/ml) showed a median survival of 23
months compared to 33 months in MM-patients with lower IL-6 values (<50 pg/ml)
though this was not statistically significant (p=0.24; Figure 2). Even at several other
cut-off values (25, 75, and 100 pg/ml) no significant correlation of serum IL-6 at
diagnosis with survival was found. Not surprisingly an elevated CRP (≥10 mg/l) was
also not associated with shorter survival. In contrast, elevated values of the estab-
lished prognostic serum marker β2M (>3 mg/l) were significantly (p=0.013) associ-
ated with a worse prognosis. Median survival time in patients with elevated β2M was
less than half the median survival time in patients with normal serum values (22
months vs. 47 months; Figure 2). Serum NCAM proved to be a relevant prognostic
factor as well. Patients with MM and a high NCAM level (≥20 U/ml) at diagnosis had
a median survival time of 22 months whereas normal levels were associated with a
median survival of 54 months (p=0.04; Figure 2).
serum interleukin-6 in paraproteinaemia and multiple myeloma
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Legend to Figure 2 (p.39):
IL-6 (<50 pg/ml): 
at start n=45; 
at 36 months n=20
IL-6 (≥50 pg/ml): 
at start n=15; 
at 36 months n=5
β2M (<3 mg/l): 
at start n=15; 
at 36 months n=10
β2M (≥3 mg/l): 
at start n=45; 
at 36 months n=15
NCAM (<20 U/ml): 
at start n=29; 
at 36 months n=17
NCAM (≥20 U/ml): 
at start n=31; 
at 36 months n=8
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Figure 2. Survival curves of patients with MM according to high or low values in
respectively IL-6, β2M and NCAM.
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Discussion
In this group of well-defined patients with newly diagnosed paraproteinaemia serum
IL-6 did not discriminate between the different diagnostic groups. Median serum
IL-6 levels were higher in MGUS compared to MM although this difference disap-
peared when all patients with a documented infection or fever were excluded. As far
as the prognostic role of serum IL-6 in MM is concerned, we are in agreement with
Kyrtsonis7 and could not demonstrate the usefulness of serum IL-6 as a prognostic
factor which is in contrast with others8-10. The established prognostic serum param-
eters β2M11 and NCAM12;13 were both prognostic factors in the CCCW multiple
myeloma patients. This underlines that we selected a representative group of patients
for this serum IL-6 study.
Studies on serum IL-6 in paraproteinaemia differ in many aspects hampering com-
parisons with our own IL-6 data (Table 3). Firstly, uniformity in the patient-popu-
lations studied is lacking. The patients were either treatment-naive, had received
treatment before or were undergoing treatment when serum IL-6 was measured.
Chapter 2
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Secondly, cut-off values for the upper normal IL-6 level in serum were either not
given7;14-17 or ranged widely from 3.2 pg/ml10 to 3,300 pg/ml9. Each study reported
a different range of values, even for normal controls (Table 3).
Thirdly, and perhaps this is the most important, serum IL-6 was either determined
by bio-assay or immuno-assay (i.e. radio-immunoassay (RIA) or enzyme-linked-
immunoassay (ELISA)). Studies using a bioassay8;18-20 all found a correlation between
serum IL-6 and disease stage in MM. High values were found in MM compared to
normal controls or patients with MGUS, and levels were higher in advanced disease.
As the final result measured in bioassays is the interaction of several biological acti-
vators and inhibitors these tests could be lacking in specificity. Immunoassay meth-
ods (ELISA, RIA) were therefore developed to measure more specifically the amount
of immunoreactive IL-6. Two studies used both a bioassay as well as an ELISA16;21.
Thaler et al confirmed a good correlation between both assays though Kiss et al
reported 15 samples being positive by bioassay which were all negative by ELISA.
Subsequent studies using only immunoassay methods reported conflicting results.
Serum IL-6 levels in MM varied from undetectable to clearly related with advanced
disease, and comparisons with normal controls, patients with MGUS or primary
Sjögren’s syndrome also yielded discrepancies not easily explained7;9;10;14;22-29.
Epitopes on circulating IL-6 can be protected from binding to monoclonal antibod-
ies by binding to α-2 macroglobulin or the soluble IL-6 receptor (sIL-6R) (Brown et
al, 1991). This ‘immunoassay-shielded IL-6’ could well retain its biological activity
and be measured in a bioassay though not in an immunoassay. Recently, knowledge
on the role of sIL-6R in MM has grown considerably giving a diverse though com-
plicated picture30. The biological effect of IL-6 is influenced by sIL-6R and the IL-
6/sIL-6R complex could amplify the effect of serum IL-6. Serum IL-6R levels are
higher in patients with MM compared to MGUS making it a promising discrimina-
tory marker31.
Fourthly, IL-6 has other biologic activities such as induction of acute phase pro-
teins32. Thus, IL-6 being a pleiotropic cytokine, is also elevated during inflamma-
tion and/or infection making it important to exclude all patients with any diagnosis
that influences the acute phase response when comparing patients with MM or MGUS
to patients in other diagnostic categories. We observed high serum IL-6 levels in
patients with MGUS. It is important to look at the definition ‘MGUS’ which is widely
used in the literature4. In most published studies on paraproteinaemia the absence of
clinical evidence for a haematological malignancy has been accepted as a definition
of MGUS. Greco15 already demonstrated the importance of clearly defining patients
with MGUS because the presence of a solid tumour markedly influenced the serum
levels of IL-6, CRP and β2M in patients with paraproteinaemia diagnosed as ‘MGUS’,
which could also be demonstrated by us.
In conclusion, although IL-6 is an important cytokine as far as the pathogenesis of
MM is concerned, the IL-6 serum value is a poor diagnostic marker in patients with
paraproteinaemia and an unreliable prognostic marker in MM.
Chapter 2
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Abstract
Serum syndecan-1 was investigated in 189 patients with newly diagnosed monoclonal
proteinaemia (MM (66), MGUS (54), provisional MGUS (no bone marrow examina-
tion performed; 69)) and 36 controls. Syndecan-1 levels ranged widely between all
diagnostic categories and were of limited discriminatory value (sensitivity 68%, speci-
ficity 78%) in newly diagnosed monoclonal proteinaemia.
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In the large majority of patients with newly diagnosed monoclonal proteinaemia (M-
proteinaemia) there is no evidence for the presence of multiple myeloma (MM), plas-
macytoma, amyloidosis, macroglobulinaemia or other haematological malignancy.
Therefore, the need for an easily obtainable serum discriminatory marker is felt. The
best-known serum marker to distinguish between these categories is the M-protein
concentration it self, but much overlap exists1. Serum syndecan-1 (CD-138) is an
independent prognostic marker in MM and is expressed on pre-B-cells, lost during
differentiation and re-expressed on normal and malignant plasma cells2,3.
We investigated the discriminatory value of serum syndecan-1 in 189 patients with
newly diagnosed M-proteinaemia registered prospectively in a population-based reg-
istry. During a three-year period 1464 patients with newly diagnosed M-proteinaemia
or MM were entered. Information on patient characteristics, laboratory tests results,
M-protein-related diagnosis, comorbidity, results of bone marrow examination and
skeletal x-rays, and therapy were documented annually. A serum sample at first diag-
nosis was frozen at –80 ºC. The set-up and contents of this registry have been
described previously4. From 867 patients with serum available, 189 were evaluable for
the present study. The other 678 sera were excluded for the following reasons: other
haematological malignancy present, insufficient clinical data concerning the stage of
disease, the serum was not taken at diagnosis or an insufficient amount was left for the
syndecan-1 determination. The diagnoses of MM and MGUS were made according
to the criteria by Durie and Salmon 5. In the absence of clinical evidence of MM or
other haematological malignancy and a low M-protein concentration (<20 g/l) the
patient is often diagnosed with MGUS and a bone marrow examination is not con-
sidered to be necessary6. For precise definition therefore, MGUS was divided in two
categories: ‘definite’ MGUS (confirmed by bone marrow examination) and ‘provi-
sional’ MGUS (no bone marrow examination performed). Control sera were used
from patients without M-proteinaemia, confirmed by protein electrophoresis.
Syndecan-1 was determined using an enzyme-linked immunosorbent assay (Diaclone
Research, Besançon, France). Median values of laboratory parameters for different
diagnostic categories were compared using Mann-Whitney’s test or Kruskall-Wallis
test when appropriate. Survival curves were made using the Kaplan Meier method and
compared with the log-rank test. Analyses were performed using SPSS 12.0 for
Windows.
Serum syndecan-1 levels of all diagnostic categories with newly diagnosed M-pro-
teinaemia are shown in Figure 1 and Table 1. The median levels were highest in MM
with significant differences between the diagnostic categories (p<0.0001), however,
a wide overlap exists. These results are in accordance with two studies on smaller
series comparing serum syndecan in MGUS and MM7,8. In contrast to Seidel but in
accordance with Maisnar, we could not demonstrate a relation between serum syn-
decan-1 levels and MM stages (Table 1; p=0.06)2;7. Using a cut-off value of 166 ng/ml
(e.g. the mean level + 2SD of normal human sera; information on kit leaflet) sensi-
serum syndecan-1 in newly diagnosed proteinaemia
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tivity and specificity were respectively 68% and 78%. Like Seidel et al we confirmed
the prognostic significance of high serum syndecan levels at diagnosis in patients with
MM2. Median time of follow-up for patients with MM still alive was 8.1 (0.9-10.2)
years. Patients with MM and high serum syndecan-1 levels (≥166 g/l; n=45) showed
a median survival of 1.3 years compared to 4.7 years in 21 MM-patients with lower
serum syndecan-1 levels (p=0.0018). In a Cox regression analysis corrected for M-pro-
tein isotype and Salmon and Durie stage, elevated serum syndecan remained of prog-
nostic importance with a hazard ratio of 3.6 (95% CI 1.7-7.6).
Figure 1. Serum syndecan levels in 226 patients with newly diagnosed M-proteinaemia.
Abbreviations: MM: Multiple myeloma, 
MGUS: definite MGUS, 
prov MGUS: provisional MGUS. 
Median serum syndecan-1 levels in ng/ml (range): Multiple Myeloma 226 (3-9120); 
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Table 1. Median serum values (ranges) of syndecan-1 in newly diagnosed patients
with M-proteinaemia.
Category N Syndecan-1 (ng/ml)
Multiple myoma (all) 66 226 (3-9120)
• MM stage I 24 194 (3-667)
• MM stage II 5 290 (160-1019)
• MM stage III 37 238 (30-9120)
MGUS 54 128 (50-656)
Provisional MGUS* 69 91 (22-494)
Control Patients 36 5 (0-52)
*) MGUS without confirmatory bone marrow examination
During an 8.8 (4.3-10.7) year follow-up of all patients alive with definite MGUS or
provisional MGUS (n=123) MM developed in only two patients at respectively 6 and
12 months. One patient had a low (83 ng/ml) and one a high (176 ng/ml) level of
serum syndecan.
In conclusion, serum syndecan-1 is an important prognosticator for patients with
MM, but this marker is of no discriminatory value in patients with newly diagnosed
M-proteinaemia.
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Abstract
A higher prevalence of solid tumours in patients with M(onoclonal) proteinaemia with-
out a co-existing haematological malignancy has been reported. We investigated this
association by linking a population-based registry of patients with newly diagnosed M-
proteinaemia (n=1464) with the Regional Cancer Registry. Patients were followed for
a median of 7.4 years for those alive. In total 167 (11%) patients with 173 solid tumours
were compared to 861 patients with ‘M-proteinaemia only’ (without a haematological
malignancy). The M-protein isoptype or level or clinical parameters did not differ
between the groups. M-protein isotype was not associated with a specific tumour type.
Standardized morbidity ratios (SMR) for nearly all solid tumours were elevated in the
year of M-protein discovery, but the excess risk disappeared during follow-up sug-
gesting selection through diagnostic investigations rather than a causal role. In this
large series of patients with both newly diagnosed M-proteinaemia and a solid tumour
no relationship could be established.
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Introduction
For many decades, it has been assumed that in patients with monoclonal (M)-pro-
teinaemia and without any evidence of a co-existing haematological malignancy, the
prevalence of solid tumours is increased suggestive of a causal relationship1-8. Further
analysis of this relationship could determine more exactly the incidence of this phe-
nomenon in patients with a solid tumour and vice versa, thereby establishing the rel-
evance of screening in cases of M-proteinaemia. To this end we linked a population-
based M-protein database9;10 to the regional cancer registry and compared solid
tumour M-protein patients with other groups in order to try to establish a time rela-
tionship between both diagnoses.
Patients and methods
Patient population
From 1991 until 1993, a population-based registry on M-proteinaemia was set up in
the region of the Comprehensive Cancer Centre West (CCCW), a geographical area
with 1.6 million inhabitants. Clinical chemists, internists, haematologists, pathologists
and other physicians reported all patients with newly diagnosed M-proteinaemia or
multiple myeloma in the CCCW-area. Information on patient characteristics, labo-
ratory tests results, and results of bone marrow examination and skeletal x-rays were
documented. The M-protein-related diagnosis, comorbidity and therapy were
recorded. Follow-up was done annually. At follow-up, clinical data, any evolution
into a haematological malignancy, appearance of any solid tumour, M-protein levels
and other relevant laboratory tests were collected from the patients’ hospital charts
or from the general physician. In total, 1464 patients have been registered. The set-
up and contents of this registry have been described previously9;10.
Diagnostic criteria for monoclonal proteinaemia and solid tumours
M-proteins were either detected by agarose or by cellulose acetate electrophoresis
depending on the method used in the various hospitals involved. For inclusion in the
registry, each M-protein had to be confirmed by immunotyping (immunofixation).
The presence of a solid tumour preferably had to be confirmed by histology, other-
wise a clinical diagnosis had to be based on at least radiological evidence of a tumour.
Cancer sites were grouped according to the World Health Organization’s
International Classification of Diseases for Oncology (ICD-O)11.
monoclonal proteinaemia and solid tumours
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Linkage to the Regional Cancer Registry
For verification and to ensure the completeness of our data on solid tumours, the
database was linked to the regional database of the Netherlands Regional Cancer
Registry12. In this cancer registry, all patients with newly diagnosed malignancies liv-
ing in the CCCW region reported by the pathology laboratories are entered. The date
of the cytological or histological confirmation constitutes the date of diagnosis. In
addition, all hospitals employ a separate registry of the discharge diagnoses. For the
present study, patient data were linked if name, sex and date of birth were identical
in both databases to exclude the probability of false-positive or false negative linkages.
Solid tumour prevalence and incidence analysis
Follow-up started at registration (between 1991 and 1993) and is still ongoing. For
the solid cancer linkage study, complete coverage with the Regional Cancer Registry
was guaranteed until January 1st 1998. Endpoints were the development of a (haema-
tological) malignancy or death, and patients still alive were censored for all other
events on January 1st 2002. First the prevalence of a solid tumour at first diagnosis was
calculated. Patients were diagnosed with an M-protein-related solid tumour if the
tumour was diagnosed within the time frame of two years, one preceding or follow-
ing the discovery of the M-protein. Thus, all malignancies that could be associated
with the M-protein, but were not present anymore due to treatment were included,
as well as any asymptomatic multiple myeloma (MM), other haematological malig-
nancy or solid tumours that developed later on. In case of a simultaneous haemato-
logical malignancy or solid tumour during this period, the M-protein was considered
to be associated with the former and not with the solid tumour.
Secondly, Standardized morbidity ratios (SMR) for the most prevalent tumours were
determined for the period between registration (1991-1993) until January 1, 1998.
Patients with newly diagnosed M-proteinaemia were at risk until the diagnosis of a
solid tumour, MM, other haematological malignancy was made or until they died.
Multiplication of person-years under observation by the age-, sex-, and period-spe-
cific incidence rates yielded the number of solid tumours expected in the M-protein
cohort if they experienced the same risk as was prevalent in the region of the CCCW.
With this method, standardized incidence rates between patient and reference group
were compared (indirect standardization) and expressed as the ratio of the incidence
rates (SMR), which may be viewed as a relative risk. Confidence limits for the SMR
were based on a Poisson distribution for the observed number of deaths13.
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Statistical methods
Statistical methods to compare the ‘M-proteinaemia Only’ versus ‘Solid Tumour
group’ included Mann Whitney’s test and in the case of case-control design, chi-
square test when appropriate. Analyses were performed using SPSS version 10. Data
were entered in the database using SPSS Data Entry version 2 (both SPSS Inc.
Chicago, Il., USA).
Results
Prevalence of solid tumours at first diagnosis of M-proteinaemia
The database consisted of 1464 patients with an initial diagnosis of M-proteinaemia.
The frequency of newly discovered cases was 31/100,000 inhabitants and 189/100,000
for people above 70 years of age9. In 271 patients, a diagnosis of MM was made, in
164 another haematological malignancy was diagnosed, but in the large majority no
explanation was found (provisional9 or definite monoclonal gammopathy of unknown
significance, MGUS) (Table 1).
In total, 173 solid tumours without any evidence of MM or other haematological
malignancy were diagnosed in 167 (11%) patients. The types of tumour found are
depicted in Figure 1. Nearly all tumours (n=167; 96%) were (adeno)carcinomas, the
other six malignancies consisted of melanomas (n=4), sarcoma (n=1) and leiomyosar-
coma (n=1).
monoclonal proteinaemia and solid tumours
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Figure 1. Distribution of solid tumours and M-proteinaemia. Two tumours were
diagnosed in six patients: bilateral breast (2), breast + pancreas, breast carcinoma +
colon leiomyosarcoma, squamous skin + melanoma, pancreas + gingiva. No percent-
age between brackets means only one tumour found. Modified from Goffinet and
colleagues19.
Solid tumour and M-protein isotype
To study whether specific tumour types were related to specific M-protein isotypes,
we selected patients with one of the six most frequently occurring solid tumours, lung
(n=40), colon (n=21), breast (n=15), prostate (n=13), bladder (n=10) and pancreas
(n=9). In all, the IgG isotype predominated (60-85%), followed by IgM (7-30%) and
IgA (0-10%). No clear preferential M-protein types were seen within specific tumour
groups.
monoclonal proteinaemia and solid tumours
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’Solid Tumour Group’ versus ‘M-proteinaemia Only Group/MGUS’
To study whether patients with M-proteinaemia and a solid tumour (i.e. ‘Solid Tumour
Group’) had specific characteristics in demographics or M-protein isotype and lev-
els, we compared this group with the patients without any malignancy (Table 1). In
the tumour group, male gender predominated. In addition, small, but significant, dif-
ferences in age were seen. The distribution of M-protein isotypes and levels was iden-
tical with the majority of patients expressing a median of 10 g/l IgG monoclonal pro-
teinaemia.
Response of the M-protein on cancer treatment
When M-proteins are causally related to a solid tumour, one would expect to find an
increase of the M-protein levels during tumour progression and a decrease after
tumour disappearance. In the Solid Tumour group, 64 out of 167 patients died within
one year after the detection of the M-protein leaving 103 patients with follow-up
data. In 25 patients (median follow-up 37 months, range 3-95 months) the M-pro-
tein was measured at least once after the first detection and therapy (if any) of the solid
tumour. Since in four patients a haematological malignancy developed (see ‘Follow-
up since entry in the M-protein database’), a relationship (rising or lowering of the
M-protein in correspondence with the progression or decrease of the tumour) could
be studied in only 21 patients. In this small group of patients, no convincing rela-
tionship was seen between the behaviour of the solid tumour and the M-protein lev-
els (data not shown).
Follow-up since entry in the M-protein database
During follow-up (last analysis 1-1-2002) a new solid tumour was detected in 23
patients in addition to those already diagnosed in the 167 patients. All of these tumours
occurred in the period 1992-1998 (see Table 2). In the years thereafter, no additional
tumours were found. Out of the 167 patients in whom a solid tumour was diagnosed
simultaneously with the M-protein, three patients developed MM (14, 56 and 65
months after the detection of the M-protein) and one patient developed a non-
Hodgkin’s lymphoma (NHL) (28 months after the detection of the M-protein).
For comparison, in the Monoclonal proteinaemia only /MGUS group, 28 developed
MM, and another 17 developed haematological malignancies, consisting of NHL
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Standardized Morbidity Ratio
Cumulative follow-up of all 1464 patients during this selected period (1991-1998)
was 3060 person-years with a median follow-up of 1.3 years (range 0-7 years) and a
median follow-up of 7.4 years (range 10 months-7 years) for those still alive.
Cumulative follow-up (measuring the time interval between the date of diagnosis of
the M-proteinaemia and the date of diagnosis of the solid tumour) for the Solid
Tumour group was 24 person-years (median less than 1 day, range 0-2.8 years). In
conclusion, most solid tumours were diagnosed simultaneously with the detection of
the M-protein (median follow-up less than one day, see above). In the first year after
the detection of the M-protein, SMR for nearly all solid tumours showed an increased
risk (range 0-50). However, all declined sharply or normalised during subsequent fol-
low-up years (Table 2).
Discussion
In this population-based registry on patients with newly diagnosed M-proteinaemia we
describe the largest series collected thus far of patients with both a solid tumour and
a M-protein but without any evidence of a co-existing haematological malignancy.
Since 1928, investigators reported an increased prevalence of solid tumours in patients
with M-proteinaemia suggesting a paraneoplastic phenomenon. For comparison with
our cohort, we selected only studies with more than 100 patients, with a description
of the related malignancy including concise histopathology and information on the
determination of the M-protein, and were left with 81- 8. Identical to our series, nearly
all solid tumours described were (adeno)carcinomas. M-proteins were mostly of the
IgG isotype and levels (if investigated) were generally lower than 30 g/l.
The co-existing tumours in this M-protein database were manifest at the diagnosis
of the M-protein in the large majority of patients. During follow-up, only a small
additional number of solid tumours were detected. Kyle and colleagues et al observed
the development of a second tumour in 15 of 241 MGUS-patients during a 20-35 year
follow-up14 and Pasqualetti and colleagues reported 31 out of 263 similar patients
who died due to a solid tumour during a median follow-up of 11.5 years15. In con-
trast, in the only prospective study investigating the incidence of haematological and
solid malignancies in patients with M-proteinaemia, Gregersen and colleagues did not
observe an increased risk of solid tumours in 1229 patients during follow-up (mean
4.8 years, range 0-15.7 years)16. Similarly to our findings, the risk for developing a
solid tumour was increased in the first year of follow-up though this risk diminished
thereafter16. Approaching the probable relationship between M-proteinaemia and
cancer the other way around yielded no association either: in two cross-sectional stud-
Chapter 4
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ies the prevalence of M-proteinaemia in patients with non-haematological tumours was
not increased when compared to the prevalence in the general population17;18.
In conclusion, we did not observe differences in clinical characteristics between
patients with ‘M-proteinaemia only/MGUS’ and patients with ‘Solid tumour and M-
proteinaemia’. There was no relation between specific solid tumours and M-protein
isotype nor did the serum level of the M-protein change after anti-tumour therapy
(although the number of patients was small in this analysis). Although risks for nearly
all solid tumours found were initially elevated in patients with newly diagnosed M-
proteinaemia, these decreased in the year after suggesting a diagnostic selection of
patients rather than a causal role.
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Abstract
Background: Prospective studies on the risk of malignant transformation in patients with
monoclonal proteinaemia of undetermined significance (MGUS) and specifically fac-
tors predictive of survival are lacking.
Objective: To determine factors predictive of malignant transformation and survival in
patients with MGUS.
Design: Prospective hospital-based cohort study.
Setting: Dutch Comprehensive Cancer Centre West comprising 1.6 million inhabitants and
15 hospitals.
Patients: Patients with newly diagnosed M-proteinaemia (n=1464) with a median age of 73
(17-103) years, included from January 1991 through December 1993 and followed
yearly.
Measurements: M-protein related diagnoses, patients’ characteristics, laboratory investi-
gations, bone marrow examinations and skeletal X-rays were registered. Main end-
points were death, or new diagnoses of multiple myeloma and non-Hodgkin’s lym-
phoma. Kaplan-Meier survival curves were compared with age and gender matched
survival data from the total Dutch population. Cumulative malignant transformation
was corrected for death using a competing risk model. Risk factors for transformation
or death were analyzed by univariate and multivariate analyses.
Results: M-protein-related diagnoses were: multiple myeloma 294 (20%), other haemato-
logical diseases 163 (11%) and MGUS 1007 (59%) consisting of definite MGUS (bone
marrow confirmed) 213 (15%) and provisional MGUS (without bone marrow confir-
mation) 794 (54%). Malignant transformation in all MGUS patients was associated
with rising M-protein levels, the IgA and IgM isotype and occurred at a yearly rate of
0.4%. All MGUS patients survived less than a matched cohort of the Dutch popula-
tion, even in the absence of M-protein-associated comorbidity. Serum albumin levels
at entry appeared highly predictive for survival.
Conclusions: M-proteinaemia is not an innocent symptom. Although malignant transfor-
mation occurs rarely, survival is shortened irrespective of comorbidity.
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Monoclonal gammopathy of undetermined significance (MGUS) is characterized by
the presence of a monoclonal protein (M-protein) in the serum and/or urine without
the evidence of multiple myeloma, amyloidosis or another haematological malig-
nancy being present1. Other M-protein associated conditions are infections, autoim-
mune diseases, organ and stem cell transplantation2. In persons of seventy years or
older the prevalence rises up to 3% making it the most commonly found immunoglob-
ulin disorder in this age group3-5. Patients with MGUS have been reported to run an
increased yearly 1-2% risk of eventually developing a malignant M-protein related
haematological malignancy, most often multiple myeloma or lymphoplasmacytic lym-
phoma6-17. However, nearly all studies on this subject are retrospective and often
single centre based. The only prospective (single centre) study thus far reported a
lower incidence of malignant transformation, but maximum follow-up was only 26
months15. In 1991 a Dutch multi-centre population-based registry was initiated that
prospectively collected all patients with newly diagnosed M-proteinaemia and/or
multiple myeloma during a three-year period. From this unique cohort clinical and
serological data offered much insight in the occurrence and prognostic factors on
multiple myeloma and (probably more interesting) non-myeloma patients with mon-
oclonal proteinaemia in the Netherlands18-24. For the first time we report on the long
term follow-up (median 9 years for those alive) of all these 1464 patients of whom 1007
(69%) were initially diagnosed with MGUS.
Patients and methods
Patients
A prospective registry on M-proteinaemia was initiated in the region of the
Comprehensive Cancer Centre West from 1991 till 1993. All patients with newly
diagnosed M-proteinaemia and/or multiple myeloma in the Midwestern part of The
Netherlands (1.6 million inhabitants and 15 hospitals in 1992) were reported by clin-
ical chemists, internists, haematologists, pathologists and other physicians. Information
on patient characteristics (age, gender, performance status), laboratory test results
(haemoglobin, leukocyte and thrombocyte counts, creatinin, LDH, alkaline phos-
phatase, calcium, albumin, total protein, M-protein isotype and concentration in
serum and urine), and results of bone marrow and skeletal X-rays were obtained.
Non-involved immunoglobulins were considered reduced if at least one of the other
immunoglobulin isotypes was reduced, respectively polyclonal IgG <6 g/l, IgA <1.0
g/l, IgM <0.5 g/l. The M-protein-related diagnosis, comorbidity and therapy were
recorded. A serum sample obtained at registration was centrally stored at –80 ºC.
Follow-up was done at least once yearly until May 1st 2004. In total, 1464 patients have
been registered. M-proteins were either detected by agarose- or cellulose-acetate
long term follow-up of a population based cohort
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electrophoresis depending on the method used in each hospital where the patient
was first seen. For inclusion in the registry each M-protein had to be confirmed by
immunotyping (usually immunofixation). The setup and contents of this registry have
been described22.
Monoclonal protein related diagnoses
Four M-protein related diagnoses were defined: Multiple Myeloma, other Haema-
tological Malignancies, ‘definite MGUS’ and ‘provisional MGUS’. We followed the cri-
teria for classification of M-protein related diagnoses made by the International
Myeloma Working Group (IMWG)25 and recently reclassified all cases. Similarly, the
diagnosis of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia was
made when the IgM-M-protein serum level was more than 30 g/l and/or bone mar-
row lymphocytosis of at least 10% was present. Definite MGUS was diagnosed if the
M-protein level was less than 30 g/l and the percentage of bone marrow plasma cells
(lymphocytes) was less than 10% in the absence of evidence of other B-cell prolifer-
ative disorders and organ or tissue impairment25. This means that according to this
classification a bone marrow examination (mandatory) and skeletal X-rays (optimal)
had to be performed25. Patients with serum M-protein levels of less than 30 g/l who
were classified as having MGUS by the treating physician, but in whom no confir-
matory bone marrow examination had been performed were included in a separate
group labeled provisional MGUS22.
End points and statistics
The primary endpoints in this study were survival and malignant transformation
defined as the development of multiple myeloma or B-cell non-Hodgkin’s lymphoma.
Survival curves were calculated with the Kaplan-Meier estimate, and subgroups were
compared using the log-rank test. Hazard rates were calculated for each potential
prognostic factor in a Cox proportional hazards model. To study which variables had
an independent influence on survival, all variables with an univariate association
(p<0.10) were entered simultaneously in a Cox proportional hazards model. As the
median age of patients with M-proteinaemia was high, survival curves of the four
diagnostic groups with M-proteinaemia were compared to the survival of an age and
sex matched cohort of the total Dutch population (Statline, Statistics Netherlands
2004). Cumulative incidence of malignant progression was calculated using a com-
peting risk model in which death without progression was the competing event26.
Potential risk factors were examined univariately in a Cox-proportional-hazards
model. All data were calculated using SPSS version 12 (Statistical Package for the
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Results
Characteristics of all patients
In total 1464 patients were included; 760 (52%) were men, 704 (48%) were women,
median age was 73 (17-103) years. Multiple myeloma was diagnosed in 294 patients
(20%). Other haematological diseases were diagnosed in 163 (11%) patients and con-
sisted of: myelodysplastic syndrome (17), lymphoplasmacytic lymphoma/Waldenström’s
macroglobulinaemia (55), other B-cell non-Hodgkin lymphoma (54), chronic lym-
phocytic leukaemia (21), cryoglobulinaemia (2), Hodgkin’s lymphoma (4), chronic
myeloid leukaemia (2), acute myeloid leukaemia (4), plasma cell leukaemia (1),
haemolytic anaemia (3). MGUS was diagnosed in 1007 (69%) patients; definite MGUS
with confirmatory bone marrow examination in 213 (21%) patients and provisional
MGUS without confirmatory bone marrow examination in 794 (79%) patients (Table
1). The provisional MGUS group was further subdivided in the following categories
related to the most probable M-protein-related internal diagnosis made by the treat-
ing physician: 1. Paraneoplastic (solid tumour present), 2. Autoimmune disease, 3.
Para-infectious and, 4. Other, e.g. those patients in whom no internal diagnosis was
made (Table 2).
Characteristics of MGUS patients
The baseline characteristics for all MGUS patients and -where appropriate- sepa-
rately for definite MGUS and provisional MGUS are reported in Table 2. There
were no significant differences between both MGUS groups but for lower M-protein
levels (<10 g/l) in provisional MGUS than in definite MGUS (Figure 1). The M-
protein isotype most often found was IgG (72.6%), followed by IgM (18.6%) and
IgA (8.5%). A biclonal M-protein was found in 107 patients (10.6%). The light chain
was κ in 64% and λ in 36%. Anaemia, defined as a haemoglobin level of less than 7.4
mmol/l (12 mg/dl) occurred in 32% and was always due to non-M-protein related
causes as was renal insufficiency (Table 2). Urine examination was performed in 533
(53%) of all MGUS patients and in 69 (7%) a urinary protein electrophoresis was
performed. Initial M-protein serum values ranged from unquantifiable (small band on
electrophoresis but not quantifiable by densitometry) to 29.6 g/l. The unquantifiable
group was categorized into the <5 g/l cohort (Figure 1). In provisional MGUS M-pro-
tein related internal diagnoses were given as well in Table 2.
long term follow-up of a population based cohort
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Table 1. Baseline characteristics of all patients with M-proteinaemia.
Multiple Other haemato- All MGUS 
myeloma (294) logical diseases (1007)
(163)
Men/Women (%) 50.3/49.7 58.3/41.7 51.3/48.7
Median age in years (range) 71 (28-93) 72 (21-94) 73 (17-103)
<40 years % 1.4 6.1 3.8
40-70 years % 46.6 34.4 35.4
70 years % 52 59.5 60.8
M-protein isotype (%)
IgG 60.3 42.3 72.6
IgA 26.9 3.1 8.5
IgD 0.3 – 0.1
IgM 0.3 52.8 18.6
light chains 9.5 1.8 0.2
non-secernating 2.4 – –
unknown (%) 0.3 – –
κ/λ (%) 66/34 75/25 64/36
Reduced immunoglobulins (%) 67 43 25
Bone marrow plasma cells 28 (1-100) 5 (1-16) 5 (0-9)
% (range)
Haemoglobin
mmol/l (range) 7.1 (1.6-10.4) 7.1 (2.6-10.1) 8.0 (2.5-11.4)
g/dl (range) 11.4 (2.6-16.8) 11.5 (4.2-16.3) 12.9 (4.0-18.4)
Serum creatinine
µmol/l (range) 106 (44-2016) 88 (53-663) 88 (27-1759)
mg/dl (range) 1.2 (0.5-22.8) 1.0 (0.6-7.5) 1.0 (0.3-19.9)
% ≥177 µmol/l (2.0 mg/dl) 14 6 7
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Figure 1. Monoclonal protein levels in MGUS. 
Upper part concerns all patients with MGUS. Lower part patients with definite
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Outcome
Follow-up time
All 1464 patients were followed for 6543 person-years (median 3.9, range 0-12.4
years) during which 1007 (69%) died. Median follow-up was 8.9 (0.4-12.0) years for
those alive and 2.0 (0-11.4) years for those who died. Total follow-up for all MGUS-
patients was 4782 person-years with a median of 4.5 (range 0-12.0) years; median
follow-up was 9.0 (0.4-12.0) years for those alive and 2.0 (0-11.4) years for those who
died. Median follow-up for those alive with definite MGUS and provisional MGUS
was not different: 8.8 (0.8-11.9) years and 9.0 (0.4-12.0) years respectively. In total 19
patients were lost to follow-up.
Survival, strong prognostic role of albumin in MGUS
The 1464 patients experienced a median survival of 4 (95% CI 3.6-4.4) years. Median
survival in multiple myeloma was 2.7 (95% CI 2.0-3.4) years and median survival was
3.6 (95% CI 2.4-4.8) years in patients with haematological diseases (Figure 2). Patients
with definite MGUS survived longer for a median of 6.7 (95% CI 4.7-8.7) years com-
pared to 4.3 (95% CI 3.6-4.9) years in those with provisional MGUS (p=0.0003). All
1007 MGUS patients experienced a median survival of 4.6 (95% CI 4.0-5.3) years
which was far below the survival in an age-matched cohort of the Dutch population
(Figure 2). In patients with provisional MGUS survival was also influenced by the
M-protein related internal diagnosis (Figure 3). Survival was worst in patients with
M-proteinaemia associated with a solid tumour (median 0.4 (95% CI 0.2-0.5) years)
compared to the patients with auto-immune disease (median 6.1 years, 95% CI (4.0-
not attained), parainfectious (median 6.1 years (95%CI 2.5-9.7) and the patients with-
out an internal diagnosis (median 4.9 years (95% CI 4.2-5.6). In a univariate analy-
sis, M-protein isotype or serum level or light chain isotype did not influence survival
in MGUS patients. However, age, gender and especially serum albumin were impor-
tant factors (Table 3, Figure 4), even when patients with solid tumour related M-
proteinaemia were excluded from the analysis (data not shown). For instance, patients
with a serum albumin of less than 30 g/l (n=208) survived for a median of 1.9 (95%
CI 1.2-2.6) years compared to patients with a serum albumin of 40 g/l or more sur-
viving for a mean of 8.5 (95% CI 8.0-9.0) years. The variables that were univariately
long term follow-up of a population based cohort
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Legend to Figure 1 (p.72):
M-protein levels are divided in six categories: 
<5 g/l = M-protein level less than 5 g/l; 
5-10 g/l = M-protein level 5 till 10 g/l; 
10-15 g/l = M-protein level 10 till 15 g/l; 
15-20 g/l = M-protein level 15 till 20 g/l; 
20-25 g/l = M-protein level 20 till 25 g/l; 
25-30 g/l = M-protein level of 25 g/l or more.
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Figure 2. Survival in multiple myeloma, other hematological malignancies, definite
MGUS and provisional MGUS compared to an age and gender matched cohort of the
Dutch population.
Figure 3. Survival in provisional MGUS patients divided by related internal diagnoses.
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related to survival (p<0.10), e.g. M-protein-related diagnosis, IMWG-status (defi-
nite MGUS versus provisional MGUS), gender, age and serum albumin, all remained
significant in the multivariate analysis (Table 3).
Table 3. Univariate and multivariate analyses on risk factors for survival in MGUS.
Univariate Multivariate
Factor HR 95%CI P HR 95%CI P
Men versus women 1.24 1.06-1.44 0.007 1.34 1.15-1.57 0.000
Age (years) <0.001 <0.001
<60 1 1
60-70 2.48 1.74-3.52 2.23 1.56-3.19
70-80 4.83 3.52-6.64 4.02 2.90-5.55
>80 8.57 6.22-11.81 7.21 5.18-10.04
Albumin (g/l) <0.001 <0.001
<30 4.29 3.35-5.49 3.12 2.41- 4.03
30-35 2.71 2.14-3.44 2.14 1.68-2.73
35-40 2.16 1.73-2.70 1.67 1.33-2.09
>40 1
missing 1.85 1.38-2.48 1.42 1.06-1.91
Provisional MGUS versus 
definite MGUS 1.44 1.18-1.76 <0.001 1.43 1.16-1.76 0.001
Internal diagnosis <0.001 <0.001
paraneoplastic 3.70 2.96-4.61 3.12 2.48-3.93
auto-immune 0.69 0.43-1.06 0.69 0.44-1.09
para-infectious 0.80 0.56-1.16 0.82 0.56-1.20
other 1 1
Serum level of M-protein g/l
All 0.99 0.98-1.00 0.44
separate for IgG 0.99 0.98-1.02 0.94
separate for IgM 0.98 0.95-1.01 0.22
separate for IgA 0.99 0.95-1.04 0.77
M-protein isotype
IgG 1 0.63
IgM 1.10 0.90-1.34 0.36
IgA 0.98 0.74-1.29 0.88
Light chain
κ/λ 1.03 0.88-1.21 0.69
long term follow-up of a population based cohort
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Figure 4. The significance of survival in MGUS in relation to presenting albumin
levels: <30 g/l: serum albumin less than 30 g/l; 30-35 g/l: serum albumin 30 till 35 g/l;
35-40 g/l: serum albumin 35 till 40 g/l; >40 g/l: serum albumin of 40 g/l or more.
Malignant transformation
During follow-up of all MGUS-patients, multiple myeloma developed in 26 patients,
of whom only 6 had been initially classified in the definite MGUS group. The trans-
formation occurred at a median interval of 2.3 (0.1-6.4) years for all MGUS patients;
1.4 and 2.3 years in definite MGUS and provisional MGUS respectively. Other
haematological malignancies (lymphoplasmacytic lymphoma (8) and other B-non-
Hodgkin’s lymphoma (4)) developed in 12 patients of whom 3 in the definite MGUS
group. The probability for MGUS-patients of developing multiple myeloma or B
cell lymphoma was 3.1% at five years and seems to plateau thereafter to 3.9% at ten
years (Figure 5). Risk of progression was not significantly different in definite MGUS
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Risk factors for malignant transformation
The univariate influence of several baseline factors on transformation was examined
using Cox regression. The only significant factors for malignant transformation were
the serum M-protein level and M-protein isotype. The estimated hazard ratio for
M-protein level was 1.148, indicating that an increment of the serum M-protein of
1 g/l increased the risk of transformation 1.16 times. The IgA isotype had the high-
est risk on malignant transformation, the IgG isotype the lowest. Gender and albu-
min were not significantly related to the risk of transformation (Table 4).
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Figure 5. Risk of malignant transformation into multiple myeloma or non-Hodgkin’s
lymphoma in all MGUS patients, using a competing risk model with death without
transformation as competing event.
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Table 4. Univariate analysis on risk factors for malignant transformation in MGUS.
Factor HR 95% CI P
Men versus women 1.44 0.75-2.73 0.27
Age (years)
<60 1.00









Provisional MGUS versus 
definite MGUS 1.16 0.56-2.39 0.69
Serum level of M-protein g/l
All 1.16 1.10-1.22 0.000
separate for IgG 1.11 1.04-1.19 0.004
separate for IgM 1.19 1.08-1.30 0.000
separate for IgA 1.27 1.13-1.43 0.000
M-protein isotype
IgG 1.00
IgM 2.37 1.09-5.12 0.001
IgA 4.45 2.00-9.90
Light chain
κ/λ 1.37 0.68-2.77 0.39
Discussion
Fifteen years ago, we initiated a registry for all newly diagnosed patients with M-pro-
teinaemia. We wondered whether we could predict if and when these patients would
progress into multiple myeloma or B cell lymphoma. Next we documented M-pro-
tein associated co-morbidity and measured overall survival. In many of these patients,
the M-protein was found accidentally. Some laboratories routinely ran a protein elec-
trophoresis when discrepancies between total serum protein and serum albumin were
found. Therefore, many patients, mostly above the age of 70, were not referred to an
Chapter 5
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internist/haematologist, neither were further tests such as a bone marrow examina-
tion performed. These patients were mostly classified as MGUS, even if they had
not undergone a bone marrow examination mandatory to fulfill the criteria of the
International Myeloma Working Group. Because we wanted to know whether the risk
of transformation and survival would differ between MGUS patients who fulfilled all
criteria versus the patients who probably were less well investigated, we decided to sub-
classify the MGUS category into provisional MGUS (no confirmatory bone marrow
performed) and definite MGUS (all criteria fulfilled). All these patients were registered
in our database, thereby well reflecting the healthcare policy in The Netherlands.
M-proteinaemia and survival
Using this large prospective study, we could demonstrate that M-proteinaemia is
associated with a shortened survival compared to an age- and gender-matched cohort
of the total Dutch population, irrespectively of the associated diagnosis. Not sur-
prisingly, survival was influenced by the presence of a solid tumor in the provisional
MGUS group. However, survival was also decreased in the absence of M-protein
associated co-morbidity as can be seen in Figures 3 and 4.
Four studies addressed survival in MGUS,1;7;8;27 of which three observed a decreased
life expectancy1;8;27. Gregersen et al demonstrated an excess of death due to infections,
heart and lung disease for which no explanation was found27.
The fact that more than half of all patients have died since the start of the study,
enabled us to study risk factors for survival in the presence of M-proteinaemia.
Remarkably, serum albumin levels at presentation appeared highly predictive for sur-
vival. In a multivariate analysis incorporating age, gender, and MGUS versus provi-
sional MGUS, serum albumin remained a strong factor, even when obviously ill
patients such as those with solid tumors were omitted from the analysis. It was pos-
sible to divide the MGUS patients by serum albumin strata, which resulted in impres-
sive survival differences, ranging from a median survival of less than 2 years for those
with serum albumin <30 g/l to more 8.5 years for those with a serum albumin >40 g/l
(Figure 4). Whereas albumin in our study was studied in MGUS patients, it is impor-
tant to realize that Greipp et al showed that serum albumin, dichotomized as above
or below 35 g/l, appeared also an important prognosticator in patients with established
multiple myeloma28.
Malignant transformation
We showed that the cumulative probability of malignant transformation was only
3.9% in 10 years (0.4% per year) when using a competing risk analysis. Given the high
incidence of death (50% and 67% at 5 and 10 years respectively), the risk of trans-
formation would have appeared higher (namely 6.6% at 10 years) if this competing-
long term follow-up of a population based cohort
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risk model had not been applied. The reasons for this observed low risk of transfor-
mation could be dual: in most older studies, the modern statistics incorporating com-
peting risk strategies had not been applied, resulting in erroneously elevated risk esti-
mates. Secondly, most studies were retrospective in nature and most often single
centre based, whereas our cohort was prospective and consisted of unselected patients.
In these retrospective studies with at least 100 patients, cumulative risks of malig-
nant transformation varied from 11% to even 51% at 15 years6-10;14;16;17;29;30. In the
largest retrospective study, Kyle observed a yearly transformation incidence of 1.2%17.
The three prospective studies published thus far, concerned only low numbers of
MGUS-patients (<70), which makes it impossible to draw firm conclusions12;15;31.
Factors associated with malignant transformation
We could confirm that the serum M-protein level, and especially the IgA and IgM
isotype were the main factors most consistently associated with the risk of malignant
transformation8;9;14;16;17;30. We calculated that for each gram M-protein per liter
increase, the risk of malignant transformation rose with 1.16.
Less often, other factors have been reported to be of prognostic importance: κ light
chain13, Bence Jones proteinuria9;14;16;29;30, raised ESR16;29;30, female sex14, age above
70 years14, bone marrow plasma cell percentage9;16 and hypogammaglobuli-
naemia9;14;16. None of these factors were significant predictors in our study, although
we observed a slightly higher (HR=1.37 (95% CI 0.68-2.77) risk on transformation
for κ versus λ M-proteinaemia. Recently, an abnormal serum free light chain ratio (κ/λ
ratio <0.26 or >1.65) was reported to be associated with malignant transformation in
MGUS32, though this novel technique is not routinely available at most laborato-
ries.
In our study, the risk of malignant transformation did not depend on whether a bone
marrow examination was performed, because we observed similar results in both
MGUS groups. The M-protein isotype and the level of M-protein at initial diagno-
sis appeared the most important prognostic factors for transformation. Even then,
the risk remained low, justifying the general health policy that in asymptomatic
patients, and in patients with solid tumors or autoimmune diseases, who present with
low levels of M-proteinaemia (<10 g/l), a bone marrow examination can be postponed
until a significant increase of the M-proteinaemia is observed. This policy has been
supported by others17, although one has to be aware of the fact that an asymptomatic
myeloma could be missed. In a previous study, using our database that also included
a large number of patients with multiple myeloma, we devised a Myeloma Risk Score
using the M-protein serum level and isotype, which identified patients with newly
diagnosed M-proteinaemia in whom the likelihood of multiple myeloma being pres-
ent was sufficiently high warranting the need for a bone marrow examination21.
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Obviously, as MGUS is associated with diseases other than haematological diseases
such as multiple myeloma and B cell lymphoma2, the clinical context in which MGUS
is seen determines the prognosis of the patient. Other associated conditions have to
be ruled out as this is of prognostic importance.
In conclusion, in our study in which the largest cohort of patients with MGUS pub-
lished thus far was prospectively followed, the risk of malignant transformation was
much lower than reported in retrospective studies. Despite this low risk of transfor-
mation, we feel that establishing the diagnosis of MGUS is not anymore of ‘unde-
termined significance’, but an important signal as it is synonymous with a shortened
survival especially when the serum albumin level is low.
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Abstract
Whether response upon chemotherapy is a prognosticator in multiple myeloma (MM)
is still not known. Therefore, the relation between survival and the rate of monoclonal
protein (M-protein) decrement during the first cycles of therapy was prospectively
assessed in 262 patients with newly diagnosed MM, treated in a phase III trial
(HOVON-16). During melphalan-prednisone therapy (MP: melphalan 0.25 mg/kg &
prednisone 1.0 mg/kg orally for 5 days every 4 weeks) M-proteins were collected
monthly. Excluded were patients with light chain disease (n=18), IgM-MM (n=1) and
no immunotyping (n=1). Out of the 242 patients studied, 75% had IgG M-protein and
25% IgA; MM stages: I: 1%, II: 35% and III: 64%. The median M-protein decrement
after the first cycle of MP was 21% for IgG and 27% for IgA, and declined to <5% after
four cycles. An obvious survival advantage was seen for patients reaching an M-protein
decrement of at least 30% after the first MP-cycle, which became significant when a
M-protein decrement of 40% or more was reached. As established prognostic param-
eters (Salmon & Durie stage, serum creatinin, and haemoglobin) remained prognos-
tically significant as well we conclude that early response to melphalan and prednisone
predicts for survival in MM.
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Introduction
Prognosis in patients with multiple myeloma (MM) is defined by β-2microglobulin
(β2M)1, serum neural cell adhesion molecule (NCAM)2, myeloma cell mass and organ
dysfunction (Salmon & Durie stages)3 and speed of proliferation (plasma cell labelling
index)4. In most MM patients the serum M-protein level reliably reflects the total
myeloma cell mass5 and response to anti-myeloma therapy is usually estimated by
serial measurements of the serum M-protein. Another favourable prognostic factor
for survival could be an early response to instituted therapy similarly to aggressive
NHL6;7 and ALL8. This has been investigated by several groups yielding contra-
dicting results. However, these generally retrospective studies mostly studied non-uni-
formly treated patients, and patient numbers were small. Therefore, we investigated
the relation between M-protein decrement-rate in relation to survival in 242 MM
patients treated with standard melphalan-prednisone (MP) therapy by prospectively
measuring M-protein levels during each cycle.
Patients and methods
In 1991 a prospective multi-centre phase III study (HOVON-16) was initiated by
the HOVON (Dutch Haemato-Oncology Cooperative Group HOVON) investi-
gating the effect of low dose interferon α-2b on progression free and overall survival
as well as the quality of life after remission-induction treatment with MP in newly
diagnosed patients with MM9. A total of 262 patients with newly diagnosed MM were
entered by 35 participating hospitals in the Netherlands and were staged according
to the criteria of Durie & Salmon3. For the present analysis 20 patients were excluded:
18 patients with light chain disease, one with IgM-myeloma and one patient in whom
the M-protein could not be immunotyped. Further patient characteristics of the
remaining evaluable 242 patients are listed in Table 1. For this analysis the data from
the first eight months during MP remission induction therapy were used.
Treatment: According to the HOVON-16 protocol all patients were treated with mel-
phalan 0.25 mg/kg and prednisone 1.0 mg/kg orally during 5 days repeated every 4
weeks. Response to treatment was measured by serial serum M-protein determina-
tions (or Bence Jones proteinuria) and MP-therapy was continued for at least 10
months even if a plateau-phase was reached earlier. If further reduction (regression)
of the M-protein was achieved MP was given for more than ten months and contin-
ued until a plateau phase was reached. Next, patients were randomised to either main-
tenance treatment with interferon-α (n=46) or no maintenance (n=44). Due to vari-
ous reasons (refusal (18), concomitant disease (9), protocol violation (6), WHO
performance status >2 (4), allotransplantation (1)) 38 (30%) patients were not ran-
domised. The median survival of the patients in both randomisation arms was iden-
tical. Therefore, survival data from all patients could be used for our study9.
early response to therapy and survival in multiple myeloma
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Statistical methods: Repeated measurement models with the serum M-protein value as
a dependent variable were used to describe the changes for both IgG and IgA M-
protein levels over time. To this end, SAS software (Proc. mixed procedure, version
8.0, SAS institute, Cary, N.C.) was used. Survival curves were generated using the life
table methods of Kaplan & Meier and compared using the log-rank test. The single
factor and multifactor statistical analyses of potential prognostic factors were carried
out using the Cox proportional hazards model. All survival analyses were performed
using SPSS version 9 (Statistical Package for the Social Sciences, Chicago, Ill, USA).
Results
Patterns of M-protein decrement: M-protein serum levels were serially determined at the
beginning and every four weeks just before the start of each cycle of MP. Per cycle,
data were available from a median (range) of 81% (77-90%) of the patients at risk. M-
protein decrements (compared to the initial M-protein serum level) were most promi-
Chapter 6
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Table 1. Patient characteristics at baseline.
All patients IgG IgA 
(n=242) (n=182) (n=60)
Male (%) 133 (55) 96 (53) 37 (62)
Female (%) 109 (45) 86 (47) 23 (38)
Age (yrs), median (range) 70 (34-91) 69 (34-91) 72 (38-84)
Median M-protein (g/l, range) 45 (7-118) 46 (9-118) 39 (7-118)
at baseline
Durie & Salmon stage (%)
IB 2 (1) 1 (1) 1 (2)
IIA 82 (34) 66 (36) 15 (25)
IIB 4 (2) 2 (1) 2 (3)
IIIA 129 (53) 96 (53) 33 (55)
IIIB 26 (10) 17 (9) 9 (15)
Creatinin
≤177 mmol/l 208 (86) 160 (88) 48 (80)
>177 mmol/l 34 (14) 22 (12) 12 (20)
Haemoglobin
<6.2 mmol/l 80 (33) 59 (32) 21 (35)
≥6.2 mmol/l 162 (67) 123 (68) 39 (65)
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Figure 1. M-protein decrements during MP therapy.
Figure 1A: Median values (and ranges) of IgA M-protein decrements during
respectively 1-8 MP cycles: 27% (-333-80); 43% (-121-100); 52% (-40-100);
64% (-7-100); 66% (-7-100); 73% (33-100); 74% (-26-100); 75% (-158-100).
Figure 1B: Median values (and ranges) of IgG M-protein decrements during
respectively 1-8 MP cycles: 21% (-71-90); 36% (-26-90); 41% (-12-90); 49%
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nent after the first cycle of MP both for IgG (27% decrement) and IgA (21% decre-
ment); an additional decrement of 15% and 16% respectively was seen after the sec-
ond cycle of MP and declined generally to less than 5% after 4 cycles (Figure 1).
Survival: In this generally elderly patient group (median age 70 years, range 35-91
years)the median survival from the time of start of MP-therapy was 31 months (range
0-88 months) for all patients (n=242); at 60 months 166 patients had died. A 50%
decrease of the M-protein level was reached by 14% of patients already after the first
MP-cycle. They subsequently survived for a median of 50 months compared to 29
months for those patients who experienced a lesser M-protein decrement (log-rank
analysis p=0.02; see Figure 2). To study whether early responders would benefit com-
pared to slow/late responders, median survival was compared for various degrees of
M-protein reached after each subsequent MP-cycle. Given the data presented in
Figure 1 we focussed on the M-protein decrements reached after the first cycle of MP.
An obvious survival advantage was seen for patients reaching an M-protein decre-
ment of at least 30% after the first MP cycle, which became significant when an M-
protein decrement of 40% or more was reached (Figure 2). The number of patients
obtaining decrements more than 60% (n=22), 70% (n=10) and 80% (n=1) was too low
for reliable analyses. The same survival analysis for patients with either an IgG or an
IgA M-protein yielded an identical pattern although numbers for the IgA subset were
rather low (Figure 3). As some investigators have reported that it takes three months
for MP to show an effect10, we repeated the same survival analysis using the 225
patients who survived for more than three months since the start of MP-therapy.
These 225 patients experienced a median survival that was not different when com-
pared to the median survival of all 242 patients (33 months vs. 31 months; n.s.).
However, a survival advantage was seen again for patients who reached a 50% M-pro-
tein decrement after three cycles of MP (median survival in responders 50 months ver-
sus 31 months). Established factors like Salmon and Durie stage, serum haemoglo-
bin, serum creatinin, and M-protein isotype were all prognosticators in these patients
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Figure 2. Survival advantage in patients with MM with increas-
ing M-protein decrement after one cycle of MP.
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Figure 3. Survival in patients with MM with increasing
M-protein decrement after the first cycle of MP,
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related to the subtype of M-protein: left IgG myeloma; 
right IgA myeloma.
Schaar-06 XP  26-09-2006  09:43  Pagina 91
Table 2. Established prognosticators.
Prognostic marker N (%) Median survival (months) Log rank
Haemoglobin
≤6.2 mmol/l 80 (33) 20 P= 0.0005
>6.2 mmol/l 162 (67) 35
Creatinin
≤177 µmol/l 208 (82) 35 P< 0.0001
>177 µmol/l 34 (14) 13
M-protein isotype
IgG 182 (75) 33 P=0.01
IgA 60 (25) 22
Salmon & Durie Stage
II 85 (35) 38 P=0.02
III 155 (64) 23
Discussion
In patients with MM we demonstrated a relation between survival and early response
to therapy as defined by the rate of M-protein reduction. Therapy consisted of the
classical melphalan/prednisone cycles and the patients in this trial belonged to the eld-
erly age group which is representative of the average age of the newly diagnosed MM-
patient.
Studies on the subject of early response to therapy and survival in MM have yielded
miscellaneous results, probably because of mostly retrospective analyses. Studies that
reported a survival disadvantage for early responding patients compared to slowly
responding patients10-13 differ in many ways from ours. They were all retrospective,
response criteria as well as time to response were different and melphalan/prednisone
dose and dosing schedules varied. No survival difference between early and slowly
responding MM-patients has also been reported14;15. Boccadoro et al, however, man-
aged to separate the early responding patients in two subgroups on the basis of a low
(<2%) or high ( ≥ 2%) plasma cell labelling index with the latter group having a worse
prognosis14. In the study by Blade et al only response to therapy (but not the rate or
degree) was associated with an improved survival15. Finally, two studies are in agree-
ment with our study16;17. McLaughlin et al retrospectively analyzed the data of only
43 out of 525 MM-patients (8%) for whom serum and urine M-protein data were
complete during the first six months of therapy16). In the only prospective study thus
far, Powles et al observed a survival advantage for patients who obtained at least a
50% M-protein decrement on infusional chemotherapy in a relatively young age
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group (median age 52 years; range 30-74)16, although this response was no longer pre-
dictive if induction was followed by high dose chemotherapy18. These data strongly
support ours, where we prospectively studied the response to classical melphalan/pred-
nisone chemotherapy in a group of elderly MM-patients representative of everyday
practice.
It has been suggested that MP-therapy takes three months to take an effect10. We
could not demonstrate any evidence for this, rather, our results indicate that response
to MP-chemotherapy is already observed after the first cycle (month) of MP-therapy.
The median M-protein decrement achieved after the first cycle of MP-therapy was
higher in patients with an IgA-M-protein compared to an IgG M-protein (27%
respectively 21%). This might be due to the shorter half-life of IgA compared to that
of IgG, 5.8 versus 23 days19, but this did not translate into a survival advantage for
patients with IgA-MM.
In conclusion, in this group of homogeneously treated elderly patients with MM, an
early response defined by an M-protein decrement of more than 40% is highly pre-
dictive for a longer survival.
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Abstract
Background: The effect of interferon-α 2b (IFN-α) on progression free and overall survival
as well as quality of life was studied in mainly elderly patients with multiple myeloma
(MM), who reached a plateau phase after melphalan/prednisone induction.
Patients and methods: In an open phase III trial 262 patients, median age 69 (range 34-91)
years, received at least 10 monthly courses of melphalan/prednisone followed by
response evaluation. Plateau phase was reached by 128 patients. Next, 90 patients were
randomized between IFN-α 2b and no maintenance therapy. Reasons for non-ran-
domization were: refusal (18), concomitant disease (9), protocol violation (6), WHO
performance status >2 (4), allogeneic transplantation (1).
Results: At a median follow-up from diagnosis of 97 (0-140) months for those patients
alive, IFN-α 2b therapy was associated with improved progression free survival (median
13.5 months versus 8.4 months from randomization) though this did not translate in a
better overall survival (41.0 versus 38.4 months). A third of patients discontinued IFN-
α due to toxicity. No differences were observed between patient groups in quality of
life.
Conclusions: IFN-maintenance therapy in MM prolongs progression free survival and, pro-
vided that the burden of toxicity is not too high, does not adversely affect quality of life.
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Introduction
In the last years the treatment-modalities of multiple myeloma (MM) have extended
enormously. High dose melphalan supported by autologous stem cell transplanta-
tion has become standard therapy for patients up to the age of 70 years. Allogeneic
and especially non-myeloablative transplantations are being explored in the same age
group. New anti-myeloma agents include immunomodulatory drugs (thalidomide,
CC15013) and the proteosome inhibitor bortezomib1. All these treatment options
have to be incorporated into studies to determine their value and place in the treat-
ment of MM. Because stem cell transplantation is often not a viable option for patients
older than 70 years with MM, melphalan and prednisone (MP) remains the standard
therapy for this age-group1. Prior to the recent development in therapies mentioned
interferon-α (IFN-α) was investigated in the treatment of MM. Two methodologi-
cally different meta-analyses on this subject, one by using individual patient data 2 and
the other by using the results of published studies3 reported increases in both pro-
gression free survival and overall survival when IFN-α was either used during induc-
tion or maintenance therapy for MM2;3. As IFN-α might still be of value in the treat-
ment of MM when transplantation is not an option, we investigated the data of the
HOVON-16 phase III trial in which IFN-α 2b maintenance therapy was compared
with no maintenance therapy after plateau phase was reached with MP in mainly eld-
erly patients with MM. With a long follow-up of 8 years for those alive, mature data
were obtained. The primary endpoints were the Progression Free Survival (PFS) and
Overall survival (OS); the secondary endpoint was quality of life (QoL).
Patients and methods
Patients
Between September 1991 and September 1997 31 HOVON centres entered patients
with newly diagnosed MM (stage IB, IIA, II B, IIIA and IIIB) and a measurable M-
protein in serum or urine. The diagnostic and staging criteria according to Salmon
and Durie were used4. No previous treatment with either chemotherapy or IFN-α was
allowed.
Study design
All patients received induction with MP. Melphalan was given at a dose of 0.25 mg/kg
for 5 days and prednisone 1.0 mg/kg for 5 days every four weeks. The minimal time
of treatment with MP was 10 months even if a plateau phase was reached earlier. If
after 10 months of treatment a further response was seen, treatment with MP had to
interferon-alpha as maintenance therapy in patients with multiple myeloma
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be given till a plateau phase was reached. Patients in plateau phase were candidate for
randomization between IFN-α 2b or no further maintenance therapy. Patients who
showed no response or who showed a relapse of their disease within 10 months after
an initial response went off study.
IFN-α 2b was started at a fixed dose of 3 million units three times per week and was
given till disease progression was observed. When WHO haematological grade 3
toxicity was encountered dose reduction to 50% was mandatory and in case of grade
4 toxicity IFN had to be stopped.
Definition of disease progression and response to treatment
Response to treatment was defined as more than 25% regression of the M-protein.
A plateau phase was reached when the mean M-protein level of the last two months
was at least 15% lower than the mean M-protein level of the preceding two months.
Disease progression was defined as an increase of more than 25% of the mean M-pro-
tein level of the last two months compared to the mean M-protein level of the pre-
ceding two months, or progression of osteolytic lesions, hypercalcaemia and or (pro-
gression of) transfusion requirement. In case of disease progression or relapse, further
therapy was given according to the discretion of the responsible physician.
Quality of life
For the QoL analysis the Rotterdam Symptom Checklist (RSCL) was used5. The
RSCL measures psychological and physical distress as experienced by cancer patients
and scores for the most important three items namely 1) physical and 2) emotional
capability and 3) performance of normal daily activities. This questionnaire was com-
pleted every three months by patients who were randomized after they reached plateau
phase and enabled us to score the quality of life of the three items in time. All the indi-
vidual scores were calculated on a scale from 0 to 100, such that a lower score implies
a better functioning or well-being.
Statistical methods
This report contains all the data as they were available on May 2004. Response data
are presented on the basis of ‘intention to treat’ (n= 262) or on the basis of those
patients who actually received any therapy (n=254). All the survival analyses were
performed using Kaplan-Meier plots and log-rank tests. Median survival estimates
were calculated with 95% confidence intervals. In the calculation of progression free
survival, patients who died without progression were censored. Response rates were
compared with the Chi square tests. The mean QoL values at different time points
were estimated using a linear mixed model and the QoL scores were compared by test-
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ing the significance of the interaction between treatment arm and time. In this way
account was taken of missing measurements due to the drop out of patients. The
sample size was calculated as follows: a mean PFS from randomization of 9 months
(SD ( 3 months) was expected. An increase of 50% of this PFS was considered as clin-
ical useful. To show such a difference with α 0.05 and a power of 0.90 a sample size
of 40 patients per treatment arm was considered sufficient.
Results
Patients characteristics
During September 1991 - September 1997 282 patients from 31 HOVON centres
were entered in the study. Not eligible were 20 patients mainly due to the absence of
a good disease parameter: stage I A (6 patients), non-secretory MM (12), insufficient
data (2). The median follow-up of all patients from start therapy was 30 months (range
0-140 months) and 97 months (0-140) for those alive. The median follow-up from
randomization was 41 months for all patients (range 0-131 months), and 78 months
for those alive (33-131). All data presented here are based upon the 262 evaluable
patients (intention to treat) although eight patients actually did not receive any ther-
apy (six died before receiving any therapy, one patient refused therapy after registra-
tion and one patient was lost to follow up shortly after the first course of therapy) and
ten were not evaluable for response (mainly insufficient data available). Patient char-
acteristics are given in Table 1.
Response rate and randomization
Response to MP was achieved in 192 (73%) patients, and 16 additional patients had
some regression of their M-protein (>15% but <25%). The overall response rate was
79%. No response or progression under MP was seen in respectively 23 (9%) and 11
(4%), whereas 56 (21%) showed a response but progressed again during the first 10
months of MP therapy. Out of the 262 patients, 128 (49%) reached a plateau phase,
and of those only 90 patients could be randomized. Reasons for non-randomization
of these 38 patients were: refusal (18), concomitant disease (9), protocol violation (6),
WHO performance status >2 (4), allogeneic transplantation (1). In total 46 patients
received IFN-α 2b and 44 patients no maintenance therapy; both groups were sim-
ilar in terms of sex, age and disease stage.
interferon-alpha as maintenance therapy in patients with multiple myeloma
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Response duration
The median PFS from randomization for patients randomized to IFN-α 2b was 13.5
months whereas those patients who did not receive any maintenance therapy showed
a median PFS of 8.4 months respectively (p=0.04) (Figure 1). The PFS at three years
was 25% in the IFN-α 2b group and only 4% in the control group. The median PFS
from diagnosis for patients randomized was 27.3 months and 20 months respectively
(p=0.01). At three years after diagnosis, the PFS was 36% in the IFN-α 2b group
versus 21% in the control group.
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Table 1. Patients’ characteristics.
All patients IF-alpha No IF-alpha 
(n=262) (n=46) (n=44)
Male/female (%) 54/46 57/43 48/52
Median age (range) years 69 (34-91) 68 (44-84) 67 (46-84)
M-protein isotype (%)
IgG/IgA/BJ/IgM/unknown 69/23/7/1/1 80/13/5/2/0 73/22/5/0/0
Stage (%)
I 1 2 2
IIA/B 34 48 34
IIIA/B 65 50 64
WHO performance (%)
0 25* 46** 36**
I 50 46 57
II 19 4 4
III 4 2
IV 1
Unknown 1 2 2
Skeletal involvement (%)
0 lesions 25 24 27
1-5 lesions 35 41 37
>5 lesions 40 35 36
* WHO performance at entry study 
** WHO performance at randomisation
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Figure 1. Progression free survival since randomization. The solid curve represents
the patients with IFN maintenance, the thin curve those patients without mainte-
nance therapy.
Survival
At the moment of evaluation (August 2004), 21 patients were still alive of whom one
was still in the study. In total 241 patients died of whom 169 of MM, 70 due to other
causes, one patient due to MP-related toxicity, and from one patient the cause of
death was unknown. The median OS of the whole patient group (n=262) was 35.1
months (95% CI 28.9-41.4 months) from the date of diagnosis (Figure 2), and 29.9
months (95% CI 23.4-36.4 months) from start of MP therapy. For patients with IgG,
IgA and Bence Jones M-protein the median survival from start of therapy was 33.4,
22.9 and 20.2 months, respectively. Survival from randomization showed an advan-
tage for patients treated with IFN-α during the first years but later survival seemed
to be similar to those patients who did not receive IFN-α (Figure 2). Median survival
from randomization was equal being 41.0 months and 38.4 months respectively, which
demonstrates that the better PFS did not translate in a better overall survival. The
median OS from diagnosis of those patients who reached plateau phase but could not
be randomized was 42.8 months (95% CI 34.5-51.1 months), versus 53.5 months
(95% CI 43.1-64.0) for patients treated with IFN-α and 50.2 months (95% CI 30.9-
69.5) for the control group.
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Figure 2. Survival since randomization. The solid curve represents the patients with
IFN maintenance, the thin curve those patients without maintenance therapy.
Toxicity
Toxicity was evaluated in the 254 patients who actually started induction therapy, of
whom 17 (7%) had to end MP-therapy because of toxicity. Myelotoxicity leading to
dose modification and/or treatment delay in the first 5 MP-cycles was observed in 155
patients (61%). One patient died (0.3%) due to neutropenic sepsis. Treatment with
IFN-α was experienced as toxic, because 17 (37%) patients had to stop because of
adverse events. Reasons why patients went off study are shown in Table 2.
Table 2. Reasons for going off study.
Reason Patients
Progression/ no response during MP 68
Toxicity MP 17
Progression after randomization 60
Toxicity IFN-α 2b 17
Protocol violation 22
Refusal to be randomized 18
Death due to comorbidity 23
Others, including 3 ineligible patients 36
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Figure 3. Estimated mean quality of life scores with 95% confidence interval. The
solid curve represents the patients with IFN maintenance, the thin curve those
patients without maintenance therapy. All scales are transformed into 0-100, in such
a way that a lower score implies better functioning or well-being.
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Quality of life
The QoL score could be calculated up to 3 years after randomization. Data are visu-
alized in Figure 3. The score for physical well being started at 20 points (out of a
range from 0-100, a score of 0 meaning no complaints at all) and although there was
a slight increase in time there was no difference between the two groups (p=0.32). The
score for psychological / emotional well- being started also at a score of 20 (out of a
range from 0-100, a score of 0 meaning no complaints at all), showed some fluctua-
tions in time, but there was no difference between the two groups (p=0.71). There was
hardly any fluctuation in the score for daily activity. Both groups started at a score of
20 (out of a range from 0-100, a score of 0 reflecting complete normal functioning)
and ended after 3 years at almost the same score without any significant difference
(p=0.77).
Discussion
In this study we demonstrated that only one third of typical elderly MM-patients
were candidate for IFN-α as maintenance therapy. Of these patients more than one
third had to stop this therapy due to the toxicity. This means that only a minority
could receive this kind of maintenance treatment for a longer period. It is thus remark-
able that in the small groups studied, a significant PFS was seen in favor of those
patients who received IFN-α. This did not translate in a better OS most likely because
the groups were too small to detect minor differences.
IFN-α maintenance therapy in MM has yielded conflicting results as was recently
addressed in a review on therapy in MM6. Two methodologically different meta-
analyses on the subject of IFN-α treatment in MM have been performed investigat-
ing nearly the same data of all randomized trials on this subject6. The meta-analysis
of the Myeloma Trialists’ Collaborative Group used individual patient data and
observed an almost similar PFS as we did. In this meta-analysis the OS was better in
patients treated with IFN-α maintenance therapy (7 months)2. However, the sur-
vival from progression was worse in the IFN-α treated patients, which may also be
the explanation that the better PFS of our patients did not lead to a better OS. The
meta-analysis by Fritz and Ludwig used published data instead of individual patient
data and also reported a benefit for the IFN-α treatment arms3. Both meta-analyses,
demonstrated a benefit of IFN-α whether it was used during induction or maintenance
therapy. The greatest benefit was seen in IFN-α maintenance therapy with an OS of
72 and 3.13 months versus a prolongation of the OS of 2.4 3 and 22 months when
IFN was used during induction therapy. For all patients (IFN-induction and IFN
maintenance therapy combined) the PFS was prolonged by respectively 6 and 4.6
months2 and OS by 42 and 3.7 months3.
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Interferon as maintenance therapy is associated with a wide range of possible serious
side effects probably especially in elderly patients. In the Nordic Myeloma Study
with patients between 55 and 81 years, more than 50% had to reduce the dose of
interferon or had to stop this treatment completely7. Also in our study a substantial
number of patients stopped the IFN-α therapy. Ludwig et al have shown in a cohort
of 355 US myeloma patients, that 58% of them were willing to undergo this kind of
potential toxic therapy if a 6 months gain of PFS or OS could be expected8. In the
Canadian study on the role of interferon maintenance therapy, patients treated with
interferon experienced substantial toxicity, but also in this study patients indicated that
the clinical benefits of interferon outweighed these negative effects9. On the other
hand, in the Nordic QoL study in patients who received chemotherapy in combina-
tion with IFN-α, the reduction of the QoL was not considered by patients to justify
the positive effect of IFN-α10.
We conclude therefore that although improvement of the PFS and sometimes also
OS can be observed when patients with MM receive IFN-α as maintenance therapy
after standard MP treatment, many will never be eligible for this kind of immunother-
apy. However, those patients that tolerate IFN-α maintenance therapy can derive
benefit in terms of substantial prolongation of both PFS and OS. Evidently, one must
conclude that IFN-α does play a role in the treatment of these patients and should
be investigated further alongside with the most recent therapeutic advances in the
treatment for multiple myeloma.
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8 Summary and general discussion
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Monoclonal proteinaemia (M-proteinaemia, formerly referred to as paraproteinaemia)
is usually associated with the presence of multiple myeloma (MM) or other haema-
tological malignancies such as chronic lymphocytic leukaemia (CLL), lymphoplas-
macytic lymphoma or other B-cell non-Hodgkin’s lymphomas (B-NHL). However,
in patients with newly diagnosed M-proteinaemia these diagnoses are established in
only 29-37%1;2.
In the absence of MM or other haematological malignancies, the M-protein is often
referred to as MGUS (Monoclonal Gammopathy of Undetermined Significance).
This definition of MGUS is loosely used to incorporate other M-protein-associated
non-haematological internal disorders like infections, autoimmune diseases and
polyneuropathy as well3.
M-proteinaemia is frequently encountered in persons older than 50 years4-10. The
incidence increases as age advances rising from 1% in the fifth to 3% and 5.7% in the
seventh4 and eighth5 decade, respectively, and has even been reported to rise to 19%
in the ninth decade11. As general life expectancy rises in the developed world and the
population ages, the chance to encounter a person with M-proteinaemia rises also
making the continuing evaluation of the diagnostic approach relevant. Incidence,
prevalence as well as follow-up of M-proteinaemia have been investigated in rela-
tively few, mostly retrospective, studies. The M-protein classification systems of Durie
and Salmon12, the British Columbia Cancer Agency13 and of the International
Myeloma Working Group (IMWG)14 require a bone marrow examination for the
confirmation of MGUS, in every day clinical practice this is often not performed
when the M-protein level is low (e.g. less than 20 g/l)15.
In 1990 the Comprehensive Cancer Centre West (CCCW) decided to initiate a
Paraprotein Task Force in order to establish a population-based registration on M-
proteinaemia. The most important aims were to develop guidelines for physicians
on MGUS, and furthermore to develop a population-based M-protein registry in
which patients with MGUS could be followed prospectively. Permission for this reg-
istry was obtained from the management and medical ethics committees of all hos-
pitals2;16. From 1991 till 1993 this population-based registry on newly diagnosed M-
proteinaemia was carried out within this CCCW region that serves a geographical area
around Leiden in the mid-western part of The Netherlands with 1.6 million inhab-
itants. All patients with newly diagnosed M-proteinaemia or MM were reported by
clinical chemists, internists, haematologists, pathologists, and other physicians. M-pro-
teins were either detected by agarose or by cellulose acetate electrophoresis depend-
ing on the method used in the various hospitals. For inclusion in the registry, each
M-protein had to be confirmed by immunotyping (immunofixation). Information on
patient characteristics (age, sex, performance status), laboratory tests results (haemo-
globin, leukocyte and platelet counts, creatinin, calcium, albumin, total protein, M-
protein type and level in serum and urine), and results of bone marrow examination
and skeletal X-rays were obtained. The M-protein-related diagnosis and therapy were
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recorded. Furthermore, a distinction was made between patients whose diagnosis of
MGUS was confirmed by a bone marrow examination versus those in whom no bone
marrow examination had been performed by the treating physician. The first group
was termed ‘definite MGUS’ and the latter ‘provisional MGUS’. A serum sample
obtained at registration was centrally stored at –80 ºC. Follow-up was performed
annually. In total 1464 patients have been registered during 1991-1993. The devel-
opment of the CCCW database and the initial findings at registration including the
development of a Myeloma Risk Score have been published in a thesis17. This thesis
elaborates on discriminatory serum parameters (interleukin-6 and syndecan), the
association between M-proteinaemia and non-haematological malignancies as well as
the final follow-up data of the whole cohort. In addition, data from the HOVON-16
myeloma study could be used to receive more insight in the kinetics of M-protein lev-
els. Using data of this study, the prognostic role of the M-protein decrement during
anti-myeloma therapy was investigated, as well as the value of interferon-alfa during
maintenance therapy.
Discriminatory serum markers in M-proteinaemia
Bone marrow examination is currently the most informative, yet time consuming and
patient unfriendly, discriminatory marker in M-proteinaemia14. Evidently, it would
be very helpful to have a serum marker that facilitates the distinction between a true
malignant plasma cell proliferation and other more benign conditions. The best-
known serum marker to differentiate between these categories is the M-protein con-
centration itself, but much overlap among these disorders exists16. Several other
tumour markers have been reported in the literature, however with ambiguous results
such as β2-microglobulin18, serum NCAM19 and C-reactive protein20.
In Chapter 2 we investigated whether serum interleukin-6 (IL-6) could serve as dis-
criminatory marker in newly diagnosed M-proteinaemia. Serum IL-6 is a pleiotropic
cytokine. It induces not only the formation of acute phase proteins21 but serves as an
autocrine and paracrine growth factor for (malignant) plasma cells as well21;22. Serum
IL-6 levels have reported to be high in patients with MM, rising during progression:
at diagnosis high serum IL-6 levels are associated with an adverse prognosis23-29. We
determined serum IL-6 levels by using an enzyme linked immunoabsorbent assay
(ELISA) in 212 well defined patients with M-proteinaemia: MM (60), other haema-
tological diseases (46), solid tumours (35), autoimmune diseases (17) and MGUS (54).
Serum IL-6 ranges in all diagnostic groups analyzed overlapped widely, and therefore
cannot serve as a discriminatory marker in newly diagnosed M-proteinaemia, even
when patients with infection or fever (42) are excluded. In MM high IL-6 levels (≥50
pg/ml) were not associated with shorter survival (p=0.24), although elevated levels of
established prognostic markers like β2M and NCAM were, signifying that we did
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choose a representative patient population. We compared our results with 20 pub-
lished studies on serum IL-6 in M-proteinaemia and/or MM and concluded that IL-
6 data have to be related to the assay used (bio- or immunoassay) and to the status of
MM (newly diagnosed, during therapy, progressive disease). Since the publication of
this paper no further studies on serum IL-6 in MM have been published. We there-
fore conclude that serum IL-6 is not specific for M-proteinaemia-related diseases
and can not serve as a reliable discriminatory or prognostic marker in M-proteinaemia
and MM.
The search for the ‘Discriminatory Serum Grail’ in M-proteinaemia continues in
Chapter 3 with the evaluation of serum syndecan-1 as a serum marker. Soluble syn-
decan-1 (CD138) is an independent prognostic marker in MM and is expressed on
pre-B-cells, lost during differentiation and re-expressed on normal and malignant
plasma cells30;31. Serum samples from a subset of 226 patients of the CCCW cohort
with newly diagnosed M-proteinaemia were analyzed. M-protein related diagnoses
were: MM (n=66), other haematological malignancies (n=37), definite MGUS (n=54),
provisional MGUS (no bone marrow examination performed; n=69) and 36 controls.
Median serum syndecan-1 levels were higher in MM (226 ng/nl) than all other diag-
nostic groups (haematological malignancies 79 ng/ml, definite MGUS 128 ng/ml,
provisional MGUS 128 ng/ml, controls 5 ng/ml; p<0.0001). However, ranges over-
lapped widely between all categories. High syndecan-1 levels (>166 ng/ml) did not pre-
dict progression of MGUS into MM, but were on the other hand associated with
worse survival in MM. The prognostic value in MM was thus reconfirmed. However,
with a sensitivity of 68% and specificity of 78%, it is of limited discriminatory value
in patients with newly diagnosed M-proteinaemia.
Up to date still no definitive discriminatory marker, other than the M-protein level
itself, in M-proteinaemia has been found.
Solid tumours and M-proteinaemia
Previous investigators reported an increased prevalence of solid tumours of up to
43% in patients with M-proteinaemia suggesting a paraneoplastic phenomenon32-
74. We investigated in Chapter 4 this possible association by determining the total
number and types of non-haematological malignancies in the CCCW cohort. The
registration of all patients in the CCCW database was extensive, the presence of non-
haematological malignancies could easily be determined. As patient data have been
subjected to additional databases, the non-haematological malignancy of patients in
this study could readily be confirmed by linkage to the Regional Cancer Registry.
Moreover, additional information on that tumour (histology, therapy) had been col-
lected and even tumours not registered in the CCCW database were added, provid-
ing a more complete picture. This joint study represents a unique example demon-
Chapter 8
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strating the importance of national registration in databases. Out of 1464 patients in
the CCCW database 167 (11%) were diagnosed with 173 solid tumours without any
evidence of MM or other haematological malignancy being present. The types of
tumour found are depicted in Figure 1, Chapter 4. Nearly all tumours (n=168; 96%)
were (adeno)carcinomas, the other five malignancies consisted of melanomas (4) and
leiomyosarcoma (1). We found no relation between tumour type/histology and M-
protein isotype. For comparison with our cohort, we selected only studies with more
than 100 patients, with description of the related malignancy including concise
histopathology and information on the determination of the M-protein, and were
left with eight studies38;46;53;56;66;67;70;72 and found similar findings on tumour type,
histology, M-protein isotype etc.
The question still remains whether the co-existence of a solid tumour and a M-pro-
teinaemia is accidental or relational. Several hypotheses have been suggested to explain
a relation between M-proteinaemia and solid tumours:
1. The M-protein is a part of the humoral immune response against solid tumours
and could exert an anti-tumour effect. There have been indeed reports of plasma
cell infiltrates surrounding solid tumours61;63;73. Long ago, five patients were
described with M-proteinaemia and carcinomas surrounded by monoclonal plasma
cells that contained the secreted M-protein, although no reactivity between the
serum-M-components and tumour antigens could be demonstrated63. A causal
relationship would require a decrease of the M-protein during successful therapy
of the solid tumour. However, data on follow-up of the M-protein after anti-
tumour therapy are scarce and do not show a change in the serum level39;55. Our
results on 21 patients confirm this lack of relationship. In 21 patients the M-pro-
tein was present as least once during follow-up without an accompanying haema-
tological malignancy. In this largest series reported thus far no clear temporal rela-
tion between tumour status (therapy) and the level of the M-protein was seen.
2. MGUS can be seen as a marker of a dysfunctioning immune system with less
immunosurveillance and hence a greater tendency to develop malignancies. If that
were the case, one would expect an increased incidence of solid tumours during fol-
low-up of patients with MGUS. Kyle et al observed the development of a second
tumour in 15 of 241 MGUS-patients during a 20-35 year follow-up1. Pasqualetti
et al reported 31 out of 263 MGUS-patients (11.8%) who died due to a solid
tumour during a median follow-up of 11.5 years75. In contrast Gregersen et al did
not observe an increased risk of solid tumours during follow-up (mean 4.8 years,
range 0-15.7 years) in 1229 MGUS patients. In their first years of follow-up the
risk for developing a solid tumour was increased, although this risk diminished
thereafter76, which gives arguments to the third hypothesis:
3. Diagnostic selection: Standardized mortality ratios were elevated in the first year
for nearly all tumour types but declined there after to normal values. The time-
dependent decrease in the risk of solid tumours in Gregersen’s study and ours can
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be explained by selection of patients through diagnostic investigations. It is likely
that during the diagnostic workup for a suspected malignancy, especially in the
presence of lytic bone lesions, protein-electrophoresis is readily performed. In two
cross-sectional studies the prevalence of M-proteinaemia in patients with non-
haematological malignancies was not increased when compared to the prevalence
in the general population58;77.
4. Age: during advancing age both the prevalence of solid tumours and of M-pro-
teinaemia increase5. This could be an explanation for the assumed relation between
M-proteinaemia and solid tumours.
In conclusion, we observed 167 patients (11.4%) with a coexistent solid tumour using
a well-defined population-based registry on M-proteinaemia. In a case-control analy-
sis we could not find any difference in clinical characteristics between patients with
‘M-proteinaemia only’ and patients with ‘Solid tumour and M-proteinaemia’. There
was no relation between specific solid tumours and M-protein isotype and during
follow-up on the M-protein no relation with the tumour could be established either.
Although risks for the most prevalent solid tumours found were elevated initially,
they decreased in the year, after suggesting a diagnostic selection of patients rather
than a causal role. This was one of the largest series of patients with M-proteinaemia
in which a true estimate of incidence and prevalence of solid tumours has been
described.
Follow-up on the total M-proteinaemia cohort
In Chapter 5 the final aim of the CCCW registry is addressed; long-term follow-up
of the whole cohort patients with M-proteinaemia registered between 1991 and 1993.
Patients with MGUS have been reported to run an increased yearly 1-2% risk of
eventually developing a malignant M-protein-related haematological malignancy,
most often multiple myeloma or lymphoplasmacytic lymphoma15;75;78-87. However,
nearly all studies on this subject were either small or retrospective and often single
centre based. All 1464 patients of the CCCW cohort were followed prospectively for
6543 person-years (median 3.9, range 0-12.4 years) during which 1007 (69%) died.
Median follow-up was 8.9 (0.4-12.0) years for those alive and 2.0 (0-11.4) years for
those who died. Total follow-up for all MGUS-patients was 4782 person-years with
a median of 4.5 (range 0-12.0) years; median follow-up was 9.0 (0.4-12.0) years for
those alive and 2.0 (0-11.4) years for those who died with no differences between
patients with definite MGUS and provisional MGUS. The 1464 patients experienced
a median survival of 4 (95% CI 3.6- 4.4) years. Patients with definite MGUS sur-
vived longer for a median of 6.7 (95% CI 4.7-8.7) years compared to 4.3 (95% CI 3.6-
4.9) years in those with provisional MGUS (p=0.0003). All 1007 MGUS patients
experienced a median survival of 4.6 (95% CI, 4.0-5.3) years which was far below the
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survival in an age-matched cohort of the Dutch population. Not surprisingly, survival
was also influenced by the M-protein related internal diagnosis especially MGUS
associated with a solid tumour (median 0.4 (95% CI 0.2-0.5) years) compared to
patients without an internal diagnosis (median 4.9 years (95% CI 4.2-5.6). In a uni-
variate analysis, M-protein isotype or serum level or light chain isotype did not influ-
ence survival in MGUS patients. However, age, gender and especially serum albumin
were important factors. For instance, patients with a serum albumin of less than 30
g/l (n=208) survived for a median of 1.9 (95% CI 1.2-2.6) years compared to patients
with a serum albumin of 40 g/l or more, who survived for a mean of 8.5 (95% CI
8.0-9.0) years. The variables that were univariately related to survival (p<0.10), e.g.
M-protein-related diagnosis, IMWG-status (definite MGUS versus provisional
MGUS), gender, age and serum albumin, all remained significant in the multivariate
analysis. The probability for MGUS-patients of developing multiple lymphoma or B
cell lymphoma was 3.1% at five years and seemed to plateau thereafter to 3.9% at ten
years. Risk of progression was not significantly different in definite MGUS compared
to provisional MGUS (log rank p=0.69). The only significant factors for malignant
transformation were the serum M-protein level and M-protein isotype. The esti-
mated hazard ratio for M-protein level was 1.148, indicating that an increment of
the serum M-protein of 1 g/l increased the risk of transformation 1.148 times. The
IgA isotype had the highest risk on malignant transformation, the IgG isotype the low-
est. Using this large prospective study, we could demonstrate that MGUS is associ-
ated with a shortened survival compared to an age- and gender-matched cohort of the
normal Dutch population, irrespectively of the M-protein associated diagnosis. The
diagnosis of MGUS is not anymore of ‘undetermined significance’, but an important
signal as it is synonymous with a shortened survival especially when the serum albu-
min level is low.
Prognostic significance of M-protein decrement rate 
in anti myeloma therapy
As nearly all malignant plasma cells secrete an intact or part of an immunoglobulin,
serial serum M-protein evaluation plays a major role in the evaluation of anti-myeloma
therapy. The M-protein isotype and level are part of the diagnostic criteria of MM
and the level of M-protein generally reflects the amount of malignant plasma cells.
Response to instituted anti-myeloma therapy is therefore usually measured by the
change of the M-protein serum level. A rise in the serum M-protein level corre-
sponding with progression, no change with no response or plateau phase and a decre-
ment obviously with response to therapy. Finally, one of the criteria of so called com-
plete response of MM after therapy requires the total absence of measurable amount
of M-protein.
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In Chapter 6 we thus investigated in MM-patients who were treated with melpha-
lan-prednisone therapy whether the rate of serum M-protein decrement was of prognostic
value.
Studies on the role of an early response to therapy and survival in MM have yielded
miscellaneous results, with most studies reporting a survival advantage for slow respon-
ders88-91, and in contrast some others for quick responders92;93.
Data of the HOVON-16 phase III trial were used in which 262 patients with MM
received classical melphalan-prednisone therapy (MP: melphalan 0.25 mg/kg & pred-
nisone 1.0 mg/kg orally for 5 days every 4 weeks). In this protocol, M-protein serum
levels were serially determined at the beginning of each cycle of MP. After reaching
plateau phase, patients were randomized to interferon-α maintenance therapy or no
maintenance therapy at all. Exclusion criteria were the presence of light chain disease
(n=18), IgM-MM (n=1) or if no immunotyping was performed (n=1). Out of the 242
patients studied, 75% had IgG M-protein and 25% IgA; MM stages were: I: 1%, II:
35% and III: 64%. The median M-protein decrement after the first cycle of MP was
21% for IgG and 27% for IgA, and declined to <5% after four cycles. An obvious sur-
vival advantage was seen for patients reaching an M-protein decrement of at least
30% already after the first MP-cycle, which became significant when an M-protein
decrement of 40% or more was reached. As established prognostic parameters
(Salmon & Durie stage, serum creatinin, and haemoglobin) remained significant as
well, we conclude that early response to melphalan and prednisone predicts for sur-
vival in MM. It has been suggested that MP-therapy takes three months to take an
effect90. We could not demonstrate any evidence for this, rather, our results indicate
that response to MP-chemotherapy is already observed after the first cycle (month)
of MP-therapy. A similar relationship has been investigated and demonstrated for
VAD-like chemotherapy93, but data on dexamethasone-thalidomide are lacking.
Maintenance therapy with interferon-α
in multiple myeloma
In Chapter 7 we further investigated the effect on progression free survival (PFS) and
overall survival (OS) of interferon-α (IFN-α) in patients that attained plateau phase
after therapy with melphalan and prednisone. This was the primary endpoint of the
HOVON-16 study; the secondary endpoint was quality of life (QoL). We demon-
strated that only one third of typical elderly MM-patients were candidate for IFN-α
as maintenance therapy. Of these patients more than one third had to stop this ther-
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apy due to the toxicity. This means that only a minority could receive this kind of
maintenance treatment for a longer period. It is thus remarkable that in the small
groups studied, a significant longer PFS was seen in favour of those patients who
received IFN-α. This did not translate in a better OS, most likely because the groups
were too small to detect minor differences. Qol was not affected by IFN-α. Evidently,
one must conclude that IFN-α does play a role in the treatment of these patients and
should be investigated further alongside with the most recent therapeutic advances
in the treatment for multiple myeloma.
The power of the CCCW database
A series of recent studies reflect the success and power of the CCCW Paraprotein
database2;16;19;94-104. A population-based database is hard to establish, but indispen-
sable for correct evaluation of the hypotheses made on a population level and corre-
sponding questions asked. Also, linking of this database with that of the Regional
Cancer Registration proved not only to be feasible but generated additional infor-
mation on the prevalence of and subsequent occurrence of solid tumours during fol-
low-up in patients with MGUS.
Investigational approaches to newly diagnosed M-proteinaemia varied widely between
physicians and hospitals17. Initial serum M-protein level and isotype were predictive
in the appraisal of the chance of a future malignant transformation, unexpectedly a
bone marrow examination at serum M-protein diagnosis was not. These results sup-
port the current practice in The Netherlands in which a bone marrow examination
is generally not advised at M-protein levels of 10 g/l or less (CBO consensus 2001105).
Patients with provisional MGUS showed an inferior overall survival probably reflect-
ing a lesser general physical condition in which the treating physician withheld fur-
ther investigation on the cause of M-proteinaemia as it would have no consequences.
In a multivariate analysis serum albumin level was highly significant in survival of
MGUS-patients. Serum albumin is established marker of disease progression in mul-
tiple myeloma106;107, reflects general nutritional status and is inversely correlated
with serum IL-6 levels107. As serum albumin is prognostically significant in both
MGUS and MM (ISS scoring system) further elaboration of this association seems
most interesting. In conclusion, this database gives an accurate documentation on
the diagnostic strategies concerning newly diagnosed M-proteinaemia during 1991-
1993 in the CCCW region. In addition, this is the first cohort study with a truly
prospective follow-up on newly diagnosed M-proteinaemia and especially MGUS.
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Inleiding
Monoclonale proteïnemie, MGUS en multipel myeloom
Alle bloedaanmaak begint bij de stamcel die tot diverse soorten bloedcellen kan uit-
rijpen, rode of witte bloedcellen of bloedplaatjes. Er bestaan diverse soorten witte
bloedcellen die samen voor de afweer zorgen. Eén van deze soorten witte bloedcel-
len zijn plasmacellen die ontstaan zijn na rijping van voorloper B-cellen tot B-lym-
focyten en uiteindelijk tot plasmacellen. Plasmacellen vormen afweerstoffen (immu-
noglobulinen) welke in het bloed terechtkomen en dienen voor de afweer tegen
bacteriën en virussen. Elke plasmacel produceert één specifiek (monoclonaal) immu-
noglobuline. Normaal worden er miljoenen soorten afweerstoffen gevormd maar als
één plasmacel gaat woekeren, leidt dat tot ongeremde aanmaak van de bij die plasmacel
horende immunoglobuline; het zogenaamde M-proteïne (Monoclonaal proteïne).
Een immunoglobuline is een complex eiwit dat bestaat uit een combinatie van 2
dezelfde zware en 2 dezelfde lichte eiwit ketens. Er zijn 5 soorten (isotypen) zware
ketens: IgG, IgM, IgA, IgD en IgE en twee soorten lichte ketens: κ en λ. Het M-
proteïne wordt benoemd naar de zware en lichte ketens waaruit het is opgebouwd
maar kan ook bestaan uit een gedeelte van een immunoglobuline, bijvoorbeeld uit
alleen zware of alleen lichte ketens. Lichte ketens kunnen ook in de urine gevonden
worden en dan spreekt men ook wel van Bence Jones eiwitten.
Multipel myeloom is de benaming van de kwaadaardige woekering van plasmacellen
in het beenmerg, in Nederland ook wel bekend als de ziekte van Kahler (genoemd naar
de Oostenrijkse prof. dr. O. Kahler, een van de eerste Europese artsen die deze ziekte
heeft beschreven). De belangrijkste complicaties van multipel myeloom zijn:
• Verdringing van het gezonde beenmerg door de plasmacel woekering. Gevolgen
kunnen zijn het optreden van bloedarmoede door onvoldoende aanmaak van rode
bloedcellen, het optreden van een bloedingsneiging door een tekort aan bloedplaat-
jes en een toegenomen vatbaarheid voor infecties door verminderde aanmaak van
witte bloedcellen en de overige normale immunoglobulinen (afweerstoffen).
• Botaantasting door de maligne plasmacellen geeft botpijnen en een verhoogde
kans op optreden van ‘spontane’ botbreuken. Ook kan het kalkgehalte in het bloed
verhoogd raken (hypercalciëmie) hetgeen weer aanleiding kan geven tot obstipatie,
dorst, uitdroging en een verlaagd bewustzijn.
• Verminderde nierfunctie door neerslag van de Bence Jones eiwitten in de nier,
uitdroging bij hypercalciëmie of een combinatie van beide.
Therapie voor het multipel myeloom bestaat voornamelijk uit diverse vormen van
chemotherapie, hooggedoseerde chemotherapie met perifere stamcel ondersteuning
voor patiënten tot en met 65 jaar en minder intensieve chemotherapie voor diegenen
die ouder dan 65 jaar zijn. Verder behoren ook de immunomodulantia zoals thalid-
omide, lenalidomide en interferon-alfa tot het therapeutisch arsenaal. Tot de onder-
Chapter 8
122
Schaar-08 XP  26-09-2006  09:45  Pagina 122
steunende therapie behoren de bisfosfonaten (om botafbraak te remmen) en bestra-
ling op ernstig aangetaste botdelen als direct effect nodig is. Een uitgebreidere bespre-
king valt echter buiten het bestek van deze inleiding.
Het vinden van een M-proteïne wordt vaak gezien als een bewijs voor de aanwezig-
heid van een multipel myeloom, een andere kwaadaardige plasmacelaandoening zoals
de ziekte van Waldenström of lymfeklier kanker (non-Hodgkin lymfoom). Echter, in
zeker tweederde van de personen bij wie een M-proteïne wordt gevonden is er geen
sprake van een hematologische maligniteit, maar lijkt het gevonden M-proteïne eer-
der het gevolg van een afweerrespons die enigszins uit balans is. M-proteïnemie wordt
ook gerelateerd aan auto-immuunziekten, infecties, na beenmergtransplantatie en bij
andere vormen van niet-hematologische maligniteiten.
Een M-proteïne in het bloed (M-proteïnemie) wordt relatief vaak gevonden op hogere
leeftijd, de prevalentie van M-proteïnemie bij personen van 70 jaar en ouder bedraagt
3% en stijgt zelfs naar 19% in de tiende decade. Studies over langdurige (retrospec-
tieve) follow-up bij M-proteïnemie laten zien dat in de loop der jaren het risico op
een kwaadaardige ontwikkeling van de M-proteïnemie steeds stijgt. Zo toonde een
recent gepubliceerde studie van Kyle uit de Mayo Clinics een jaarlijks risico op
maligne ontaarding van circa 1% per jaar aan en was het cumulatieve risico op maligne
ontaarding 30% na 25 jaar follow-up. Daarom moeten patiënten met M-proteïnemie
levenslang vervolgd worden. In dit licht is de benaming die Kyle gaf aan een M-pro-
teïne zonder aanwijzingen voor een hematologische maligniteit begrijpelijk: MGUS
(Monoclonal Gammopathy of Undetermined Significance).
IKW cohort
In 1991 werd door het Integraal Kankercentrum West (IKW) de Paraproteïne
Stuurgroep in het leven geroepen om een onderzoek naar M-proteïnemie in de regio
van het IKW te initiëren en begeleiden (de oude naam voor M-proteïne was para-
proteïne). Dit gebied omvat een geografisch gebied rondom Leiden met destijds in
totaal 1.6 miljoen inwoners. Doel was om inzicht te krijgen in de incidentie, preva-
lentie en bij detectie gestelde M-proteïne-geassocieerde diagnosen. Tevens was men
geïnteresseerd in het beleid van de artsen bij nieuw gediagnosticeerde M-proteïne-
mie, toepassing en ontwerp van klinische beslisregels en vooral ook in de uitkomst op
lange termijn bij alle patiënten met een MGUS.
Alle nieuw gediagnosticeerde patiënten met een M-proteïne werden aangemeld door
klinisch chemici, hematologen, pathologen en andere artsen. M-proteïnemie werd
vastgesteld met agarose- of met cellulose electroforese afhankelijk van de per zie-
kenhuis gebruikte methode. Om geïncludeerd te worden moest elk M-proteïne
bevestigd worden door immunotypering (immunofixatie). Patiënt kenmerken (leef-
tijd, geslacht, conditie), laboratorium uitslagen (o.a. hemoglobine gehalte, leukocy-
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ten en trombocyten aantallen, nierfunctie, calcium, albumine en totaal eiwit spiegels,
M-proteïne isotype en gehalte in serum en urine) evenals de uitslagen van been-
mergonderzoek en skeletfoto’s werden (anoniem) vastgelegd in een grote database.
De M-proteïne gerelateerde diagnose, comorbiditeit en therapie werden eveneens
geregistreerd. Bij inclusie werd een serummonster ingevroren (–80 ºC). Jaarlijks wer-
den de patiënten gevolgd. Toestemming voor deze registratie werd verkregen bij alle
medisch ethische commissies van alle ziekenhuizen. In totaal werden 1464 patiënten
geïncludeerd.
De patiënten werden initieel ingedeeld in vijf groepen op basis van M-proteïne gere-
lateerde diagnose: 1. Multipel myeloom (n=261, 18%), 2. Andere hematologische
maligniteit (n=160, 11%), 3. MGUS (n=208, 14%), 4. Interne ziekte (n= 209, 14%)
en M-proteine eci (e causa ignota) (n=626, 43%).
Serum merkers
Interleukine 6 en syndecan-1
Beenmergonderzoek is momenteel het meest informatieve maar eveneens het meest
patiënt onvriendelijke discriminerende onderzoek in M-proteïnemie. Voor de prak-
tijk zou het veel handiger zijn als er een serum merker bestond waarmee er een onder-
scheid gemaakt zou kunnen worden tussen een kwaadaardige of goedaardige oorzaak
van de gevonden M-proteïnemie.
In hoofdstuk 2 is onderzocht of serum interleukine-6 (IL-6) als een discriminerende
factor van waarde is bij patiënten met een nieuw gediagnosticeerde M-proteïnemie.
IL-6 is niet alleen betrokken bij de vorming van acute fase eiwitten maar functio-
neert ook als een autocriene en paracriene groeifactor voor (maligne) plasma cellen.
Serum IL-6 spiegels werden bepaald in 212 duidelijk omschreven patiënten met M-
proteïnemie: multipel myeloom (60), andere hematologische ziekten (46), solide
tumoren (35), auto-immuunziekten (17) en MGUS (54). IL-6 waarden in alle dia-
gnostische groepen overlapten en serum IL-6 fungeert daarmee onvoldoende als een
discriminerende marker in M-proteïnemie; zelfs wanneer patiënten met koorts of
een infectie (n=42) van deze analyse uitgesloten werden. In patiënten met multipel
myeloom waren hoge IL-6 spiegels (≥ 50 pg/ml) niet geassocieerd met een slechte
prognose maar waren verhoogde waarden van bekende prognostische parameters als
β2M and NCAM dat wel. Dit houdt in dat wij een representatieve patiënten popu-
latie met multipel myeloom geselecteerd hadden.
Voorts bleek na een kritische revisie van alle gepubliceerde studies over serum IL-6
in M-proteïnemie en/of multipel myeloom dat IL-6 data gerelateerd moeten worden
aan de gebruikte bepalingsmethode (biologische- of immunologische bepaling) en
aan de status van multipel myeloom (nieuw gediagnosticeerd, gedurende therapie,
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progressieve ziekte). Concluderend kan gesteld worden dat serum IL-6 noch fun-
geert als een discriminerende merker bij nieuw gediagnosticeerde M-proteïnemie,
noch als een prognostische parameter in multipel myeloom.
In hoofdstuk 3 wordt een volgende serum parameter, syndecan-1, geëvalueerd als dis-
criminerende serum marker in M-proteïnemie. Syndecan-1 is een in de celmembraan
ingebed eiwit en is betrokken bij celdeling, cel-cel en cel-omgeving interacties. Serum
syndecan-1 (CD138) is een onafhankelijke prognostische marker in MM, komt tot
expressie op pre-B-cellen, verdwijnt bij differentiatie en wordt vervolgens weer tot
expressie gebracht op normale en maligne plasmacellen. Syndecan-1 werd in het
serum van 226 patiënten van het IKW-cohort met nieuw gediagnosticeerde M-pro-
teïnemie bepaald. M-proteïnemie gerelateerde diagnosen waren: multipel myeloom,
(n=66), hematologische maligniteiten (n=37), MGUS (n=54), provisionele MGUS
(geen beenmergonderzoek uitgevoerd; n=69) and 36 controle personen. Mediane
serum spiegels van syndecan-1 waren hoger in multipel myeloom (226 ng/nl) verge-
leken met alle andere diagnostische categorieën (hematologische maligniteiten 79
ng/ml, MGUS 128 ng/ml, provisionele MGUS 128 ng/ml, controle 5 ng/ml;
p<0.0001). Echter, tussen alle categorieën was er een sterke overlap van syndecan-1
waarden. Hoge waarden van serum syndecan-1 (>166 ng/ml) voorspelden geen pro-
gressie van MGUS naar multipel myeloom, maar waren wel geassocieerd met een
slechtere overleving binnen de groep van multipel myeloom. De prognostische waarde
in multipel myeloom werd dus bevestigd, maar met een sensitiviteit van 68% en een
specificiteit van 78% is serum syndecan-1 van beperkte discriminerende waarde bij
patiënten met nieuw gediagnosticeerde M-proteïnemie.
Solide tumoren en M-proteïnemie
In het verleden werd bij patiënten met M-proteïnemie een toegenomen prevalentie
van solide (niet hematologische) tumoren tot 43% gerapporteerd hetgeen een para-
neoplastisch verschijnsel suggereerde. We onderzochten in hoofdstuk 4 deze moge-
lijke relatie door in het IKW M-proteïnemie cohort het totaal aan niet-hematologi-
sche maligniteiten te bepalen bij registratie en gedurende follow-up. De sterkte van
database onderzoek is dat deze aan andere databases te koppelen zijn mits een gemeen-
schappelijke parameter gevonden kan worden, in dit geval dezelfde patiënt. Derhalve
werd de IKW M-proteïnemie database gekoppeld aan de regionale database van de
Kankerregistratie. Hierdoor kwam tevens additionele informatie vrij over de tumor
(histologie, therapie) en werden tumoren toegevoegd die niet bekend waren in de
M-proteïne database waarmee deze database compleet gemaakt werd. Van de 1464
patiënten in de IKW-database werden er bij 167 (11%) patiënten 173 solide tumo-
ren gevonden zonder dat er een multipel myeloom of een andere maligne hematolo-
gische tumor aanwezig was. De typen tumor die gevonden werden staan in figuur 1;
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hoofdstuk 4. Bijna alle tumoren (n=168; 96%) waren (adeno)carcinomen, de andere
zes tumoren bestonden uit melanomen (4), één sarcoom en één leiomyosarcoom. We
konden geen relatie aantonen tussen histologie en M-proteïne isotype. Ter vergelij-
king met ons cohort selecteerden we uit de literatuur alleen studies met ten minste
100 patiënten waarbij nauwkeurige gegevens over tumor histopathologie en infor-
matie over het M-proteïne gegeven werden. Er bleven 8 studies over waarin over-
eenkomstige gegevens over tumortype, histologie en M-proteïne isotype gevonden
werden. Tevens identificeerden we 21 patiënten met een solide tumor bij wie zich
gedurende follow-up geen hematologische maligniteit ontwikkelde en het M-prote-
ïne minstens nog één keer bepaald was. Deze patiënt gegevens werden gebruikt om
een relatie tussen beide fenomenen aan te kunnen tonen dan wel uit te sluiten. In het
geval van een relatie was de verwachting dat het M-proteïne gehalte zou dalen na
therapie en stijgen bij progressie van de tumor. Dit bleek echter niet het geval te zijn,
er was geen enkele relatie tussen tumorstatus en M-proteïne gehalte. Als laatste werd
het relatieve risico op een solide tumor bepaald bij die patiënten die een M-proteï-
nemie zonder geassocieerde maligniteit hadden. Dit relatief risico was verhoogd in
het eerste jaar voor alle tumortypes maar daalde daarna naar een normaal risico in de
daarop volgende jaren. Aangezien de meeste tumoren binnen het jaar na detectie van
het M-proteïne gevonden werden suggereert dit meer een diagnostische selectie van
patiënten dan een causale rol. Het is makkelijk voor te stellen dat bij de verdenking
op de aanwezigheid van een maligniteit, zeker bij lytische bothaarden, er laagdrem-
pelig een eiwit electroforese ingezet wordt. Er is dus geen causale relatie tussen M-
proteïnemie en een solide tumor, evenmin is het risico op een maligniteit in de jaren
daarna vergroot.
Follow-up M-proteïnemie cohort
Patiënten met MGUS lopen een jaarlijks risico van 1-2% om een maligne transfor-
matie te krijgen naar een multiple myeloom of B-cel non-Hodgkin lymfoom. Deze
gegevens komen uit grote retrospectieve studies. Er is slechts één prospectieve stu-
die naar het risico op maligne transformatie in MGUS maar deze bevat slechts 64 pati-
enten met een te korte follow-up om duidelijke uitspraken te kunnen doen. In hoofd-
stuk 5 worden de follow-up gegevens van het gehele IKW-cohort besproken. In
totaal werden 1464 patiënten geregistreerd; 760 (52%) mannen, 704 (48%) vrouwen,
met een mediane leeftijd van 73 (17-103) jaar. Multipel myeloom werd gediagnosti-
ceerd in 294 patiënten (20%). Andere hematologische ziekten werden in 163 (11%)
patiënten gediagnosticeerd en bestonden uit: myelodysplastisch syndroom (17), lym-
foplasmacytoid lymfoom/Waldenström’s macroglobulinemie (55), andere B-cel non-
Hodgkin lymfomen (54), chronische lymfatische leukemie (21), cryoglobulinemie
(2), Hodgkin lymfoom (4), chronische myeloide leukemie (2), acute myeloide leuke-
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mie (4), plasma cel leukemie (1), hemolytische anemie (4). MGUS werd vastgesteld
in 1007 (69%) patiënten; definitieve MGUS ondersteund door beenmergonderzoek in
213 (21%) patiënten en provisionele MGUS waarbij een bevestigend beenmerg-
onderzoek ontbrak in 794 patiënten. Tevens werd van de laatste groep ook de M-pro-
teïne gerelateerde diagnose geregistreerd: solide tumor, infectie en auto-immuun
ziekte. Er waren verder geen klinisch relevante verschillen tussen beide MGUS-groe-
pen. Totale follow-up voor alle 1464 patiënten was 6543 persoonsjaren (mediaan 3.9,
range 0-12.4 jaren) gedurende welke 1007 (69%) overleden; van 19 patiënten waren
geen follow-up gegevens bekend. Mediane follow-up was 8.9 (0.4-12.0) jaar voor die-
genen die in leven waren en 2.0 (0-11.4) jaren voor diegenen die overleden waren.
Totale follow-up voor alle MGUS patiënten was 4782 persoons-jaren met een medi-
aan van 4.5 (range 0-12.0) jaren. Significant voor overleving waren zowel in de uni-
variate als in de multivariate analyse de M-proteïne-gerelateerde diagnose, defini-
tieve MGUS versus provisionele MGUS, geslacht, leeftijd en serum albumine.
Aangezien albumine ook voorspellend is voor overleving bij nieuw gediagnosticeerde
myeloom patiënten in de recent ontwikkelde ISS score (International Staging System)
dient deze associatie zeker verder onderzocht te worden. Alle MGUS-patiënten over-
leefden korter dan een op leeftijd en geslacht gematcht cohort van de Nederlandse
bevolking. Factoren geassocieerd met een verhoogde kans op maligne transformatie
naar een multipel myeloom of B-cel NHL waren alleen serum M-proteïne gehalte en
isotype. De kans op maligne transformatie was trouwens lager dan eerder gerappor-
teerd in retrospectieve studies, ca 0,4% per jaar en totaal 3,9% op 10 jaar. Hierbij werd
gebruik gemaakt van een zgn ‘competing risk’ analyse waarbij patiënten die overle-
den niet meer meetelden in de risicobepaling voor maligne transformatie.
Concluderend kan gesteld worden dat de aanwezigheid van een MGUS wel implicaties
heeft, zeker bij een verlaagd serum albumine is de overleving significant verminderd.
HOVON-16
Snelheid van monoclonaal proteïne afname tijdens therapie en kwaliteit
van leven tijdens interferon-alfa
Seriële bepaling van het serum M-proteïne tijdens chemotherapeutische behande-
ling voor multipel myeloom een belangrijke rol bij de evaluatie hiervan. Het M-pro-
teïne isotype en serumgehalte vormen deel van de diagnostische criteria van multi-
pel myeloom en het gehalte aan serum M-proteïne is een directe afspiegeling van de
plasmacel tumormassa. Het effect van anti-myeloom therapie wordt daarom geme-
ten aan de hand van de verandering van het serum M-proteïne concentratie. Een stij-
ging van het M-proteïne gehalte staat gelijk aan ziekte progressie, een daling aan
afname van ziekte activiteit en geen verandering van de M-proteïne concentratie aan
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stabiele ziekte activiteit. Zo is één van de criteria voor complete respons het niet meer
aantoonbaar zijn van het M-proteïne en spreekt men bij het stabiel blijven van het M-
proteïne na therapie over de plateaufase.
Studies over de snelheid van respons op therapie en overleving in MM hebben in het
verleden tegenstrijdige resultaten opgeleverd. De meeste studies lieten een overle-
vingsvoordeel voor langzame responders zien, sommige voor snelle responders op
therapie. In hoofdstuk 6 hebben we onderzocht of de snelheid waarmee het M-pro-
teïne tijdens therapie daalde (= snelheid van respons op therapie) van prognostisch
belang was. Data van de HOVON-16 fase III trial werden gebruikt waarin 262 pati-
ënten met multipel myeloom het klassieke orale melfalan-prednison schema (melfa-
lan 0.25 mg/kg & prednison 1.0 mg/kg oraal 5 dagen per 4 weken) kregen. Serum M-
proteïne spiegels werden bij aanvang van therapie en telkens voor de start van elke
nieuwe melfalan-prednison cyclus per 4 weken bepaald. Nadat plateaufase bereikt
was werden de patiënten gerandomiseerd tussen wel of geen onderhoudstherapie met
interferon-alfa. Uitgesloten werden patiënten met lichte keten myeloom (n=18), IgM-
myeloom (n=1) en ontbrekende immunotypering. Van de 242 patiënten had 75%
een IgG M-proteïne en 25% IgA; myeloom stadia: I: 1%, II: 35% and III: 64%.
De mediane M-proteïne daling na de eerste cyclus van melfalan-prednison was 21%
voor IgG en 27% voor IgA, en nam af naar < 5% na 4 melfalan-prednison cycli. Een
duidelijk overlevingsvoordeel werd gezien voor patiënten die een M-proteïne daling
van minstens 30% meteen na de eerste melfalan-prednison kuur bereikt hadden; dit
verschil werd significant wanneer ten minste een daling van 40% werd bereikt.
Aangezien bekende prognostische variabelen (Salmon & Durie stadium, serum cre-
atinine, en hemoglobine) hun prognostische waarde behielden concluderen we dat
snelle respons op melfalan-prednison therapie van prognostisch belang is in multipel
myeloom. Eerder is gesuggereerd dat melfalan-prednison therapie drie maanden
nodig heeft om effect te geven, onze resultaten laten zien dat respons op melfalan-
prednison therapie al gezien wordt na één kuur. De mediane daling van het M-pro-
teïne na één kuur melfalan-prednison was hoger in patiënten met een IgA isotype
vergeleken met het IgG isotype (27% respectievelijk 21%). Dit kan komen door een
kortere halfwaardetijd van IgA versus IgG (5.8 versus 23 dagen) maar dit vertaalde zich
overigens niet in een overlevingsvoordeel voor patiënten met IgA-myeloom.
In hoofdstuk 7 is wederom gebruik gemaakt van hetzelfde patiëntenbestand van de
HOVON-16 studie. Na inductie behandeling met melfalan-prednisonkuren werd er
bij die patiënten die een plateaufase behaalden gerandomiseerd tussen wel of geen
onderhoudsbehandeling met interferon-alfa. De primaire eindpunten van de
HOVON-16 studie waren progressievrije overleving en algehele overleving, het
secundaire eindpunt was kwaliteit van leven. Slechts één derde van alle (typisch de
oudere) patiënten in deze studie kwam in aanmerking voor onderhoudstherapie met
interferon-alfa. Van deze patiënten moest vervolgens weer meer dan éénderde deze
onderhoudstherapie stoppen vanwege toxiciteit. Dit betekent dat maar een minder-
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heid van alle multipel myeloom patiënten deze onderhoudstherapie gedurende lan-
gere tijd aankon. Daarmee is het wel opmerkelijk dat hoewel de bestudeerde groepen
klein waren, een significant langere progressievrije overleving werd gezien in die pati-
ënten die interferon-alfa kregen. Dit vertaalde zich niet in een langere algehele over-
leving, zeer waarschijnlijk omdat de groepen te klein waren om significante verschil-
len te detecteren. De kwaliteit van leven werd niet beïnvloed door interferon-alfa.
Concluderend moet gesteld worden dat interferon-alfa nog steeds een rol speelt in
de behandeling van multipel myeloom en verder onderzocht moet worden samen
met de nieuwste ontwikkeling in de therapie van multipel myeloom.
De kracht van de IKW database
Alle artikelen die uit het Paraproteïne Cohort zijn ontstaan zijn een teken van de
kracht en het succes van een grote populatie database1-14. Een populatie-database is
niet eenvoudig op te zetten, maar onmisbaar als men hypothesen op bevolkingsniveau
wil onderzoeken. Tevens hebben wij laten zien dat ook koppelen met een andere
grote database, namelijk die van de regionale Kankerregistratie niet alleen mogelijk
was maar ook meerwaarde bood. De benadering van de patiënt met nieuw gediag-
nosticeerde M-proteïnemie verschilde per arts en per ziekenhuis. Uiteindelijk bleek
uit onze follow-up data dat het verrichten van een beenmergonderzoek om een
MGUS goed te inventariseren niet relevant te zijn voor de inschatting op de kans op
maligne ontaarding. Dit in tegenstelling tot het serum gehalte van het M-proteïne en
isotype. Deze waren wel van belang, de kans op maligne ontaarding steeg met het stij-
gen van het serum M-proteïne gehalte, en tevens was de kans op maligne ontaarding
het hoogst bij het IgA en het laagst bij het IgG isotype. Deze resultaten ondersteu-
nen het in Nederland gevoerde beleid zoals verwoord in de CBO richtlijn
‘Monoklonale Gammopathie’ uit 2001 waarin een beenmerg onderzoek in het alge-
meen niet geadviseerd wordt bij een serum M-proteïne gehalte van minder dan 10 g/l
of minder.
Overleving in patiënten met MGUS bleek afhankelijk van geslacht, leeftijd, MGUS-
status maar ook opvallend van serum albumine. Serum albumine is een bekende mar-
ker van ziekte progressie in multipel myeloom, maar geeft ook de voedingsstatus weer
en is onevenredig gecorreleerd met serum IL-6 spiegels. Aangezien serum albumine
ook prognostisch van belang is in het nieuwe ‘International Staging System’ voor
multipel myeloom valt er veel voor te zeggenen deze relatie uit te diepen.
In conclusie, deze database heeft een gedetailleerd beeld van diagnostische strate-
gieën in nieuw gediagnosticeerde M-proteïnemie in het IKW gebied gegeven maar
is tevens ook de grootste prospectieve studie in M-proteïnemie tot nu toe.
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β2M Beta-2-microglobulin
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(Integraal Kanker Centrum West; IKW)
CRP C-reactive protein
HOVON Hematologie Oncologie Volwassenen Nederland
IFN-alpha Interferon-alpha
IL-6 Interleukin-6
IMWG International Myeloma Working Group
MM Multiple Myeloma, also known as ‘Kahler’s disease’ or ‘Rustizky’s
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M-protein(aemia) Monoclonal Protein(aemia)
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MP Melphalan-Prednisone chemotherapy
NCAM Neural Cell Adhesion Molecule
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Paraprotein(aemia) Former name for M-protein(aemia)
PFS Progression-free survival
QoL Quality of life
SMR Standardized Mortality Ratio
WHO World Health Organisation
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